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Abstract: Tumor heterogeneity is a confusing finding in the assessment of neoplasms, 
potentially resulting in inaccurate diagnostic, prognostic and predictive tests. This tumor 
heterogeneity is not always a random and unpredictable phenomenon, whose knowledge 
helps designing better tests. The biologic reasons for this intratumoral heterogeneity would 
then be important to understand both the natural history of neoplasms and the selection of 
test samples for reliable analysis. The main factors contributing to intratumoral heterogeneity 
inducing gene abnormalities or modifying its expression include: the gradient ischemic 
level within neoplasms, the action of tumor microenvironment (bidirectional interaction 
between tumor cells and stroma), mechanisms of intercellular transference of genetic 
information (exosomes), and differential mechanisms of sequence-independent 
modifications of genetic material and proteins. The intratumoral heterogeneity is at the 
origin of tumor progression and it is also the byproduct of the selection process during 
progression. Any analysis of heterogeneity mechanisms must be integrated within the 
process of segregation of genetic changes in tumor cells during the clonal expansion and 
progression of neoplasms. The evaluation of these mechanisms must also consider the 
redundancy and pleiotropism of molecular pathways, for which appropriate surrogate 
markers would support the presence or not of heterogeneous genetics and the main 
mechanisms responsible. This knowledge would constitute a solid scientific background 
for future therapeutic planning. 
Keywords: neoplasm; tumor heterogeneity; topographic compartments; tumor 
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1. Introduction 
Intratumor heterogeneity in human tumors is a widespread phenomenon of critical importance for 
tumor progression and the response to therapeutic intervention, and it is a key variable to understand 
tumor natural history and potential response to therapy. It is inherent to neoplasms from early stages 
and is also the byproduct of tumor progression as genetic abnormalities accumulate. It has normally 
been assumed that tumor progression is a linear process, with metastasis being a late event, but this 
model would not match well with the heterogeneity: the invasive capability can be acquired early and 
result in metastasis from early neoplasms that already show genetic and kinetic features of established 
malignancies, even for those of low nuclear grade. Human cancers frequently display substantial   
intra-tumor heterogeneity in virtually all-distinguishable phenotypic features, such as cellular 
morphology, gene expression, metabolism, motility, and proliferative, immunogenic, angiogenic, and 
metastatic potential [1–3].  
Any current general definition of neoplasm (“cellular disease characterized by abnormal growth 
regulatory mechanisms”) is descriptive and difficult to apply routinely; working definitions are 
required. Biologically, neoplasms develop through acquisition of capabilities that involve tumor cell 
aspects and modified microenvironment interactions, resulting in unrestricted growth due to a stepwise 
accumulation of cooperative genetic alterations that affect key molecular pathways. The correlation of 
these molecular aspects with morphological changes is essential for better understanding of essential 
concepts as early neoplasms/precancerous lesions, progression/blocked differentiation, and intratumor 
heterogeneity [4,5]. The acquired capabilities include self-maintained replication (cell cycle dysregulation), 
extended cell survival (cell cycle arrest, apoptosis dysregulation, and replicative lifespan), genetic 
instability (chromosomal and microsatellite), changes of chromatin, transcription and epigenetics, 
mobilization of cellular resources, and modified microenvironment interactions (tumor cells, stromal 
cells, extracellular, endothelium). The acquired capabilities defining neoplasms are the hallmarks of 
cancer, but they also comprise useful tools to improve diagnosis and prognosis, as well as potential 
therapeutic targets.  
The introduction of new markers has improved the diagnostic precision, but can potentially result in 
major changes in prevalence and uncertainties for particular lesions. The current WHO classifications 
of tumors incorporate new developments based in pathology and genetics, the leading criteria still 
being morphological: molecular findings complement the histological evaluation without replacing it. 
The acquired capabilities of neoplasms include tumor cell aspects (self-maintained replication, longer 
cell survival, genetic instability), and the interaction tumor cell-tissue microenvironment (induction of 
neoangiogenesis, invasion and metastasis) [6]. The development of clinically detectable tumors 
requires the accumulation of a number of cooperative genetic alterations, regardless of its order [7]; the 
evidence available suggest that 5–7 genetic alterations are required for clinically detectable tumors, 
correlating with morphological progression in some locations. These capabilities are not equally 
relevant at different stages during tumorigenesis, as highlighted by careful morphological evaluations 
(Figure 1).  Int. J. Mol. Sci. 2012, 13 1954 
 
 
Figure 1. Morphological evaluation of neoplasms and development of oncology. 
Histopathology, as the gold standard of tumor diagnosis, has set up the bases and criteria 
for the concept of early neoplasms (I showing encapsulated tumor of epithelial cells, A, 
with central area of edema, C, and a transitional zone, B; D represent the tumor capsule) 
and carcinomas in situ (II shows a breast lobular carcinoma in situ). Histopathology is 
contributing to a better understanding of the heterotypic cell biology (III to V reveal tumor 
cells, blood vessels, inflammatory/immune cells, and stroma; tumor cells and stroma are 
highlighted by direct immunofluorescence for E-cadherin, green, and integrin, red), the 
biologic progression/dedifferentiation that has been linked to hypoxic conditions and has 
been frequently reported in recurrent tumors (VI and VII shows well and poorly differentiated 
squamous cell carcinoma, respectively, in a recurrent neoplasm), and the intratumor 
heterogeneity and segregation of tumor cells in predominantly expansile internal compartments 
IX and X) and predominantly invasive peripheral compartments (XI and XII). The 
expression of hypoxia up-regulated genes is predominantly observed in the internal 
compartments (green immunofluorescence for HIF-1 in the example). 
 
2. Tumor Cell Segregation 
Intratumor heterogeneity comprises both tumor cells and heterotypic components 
(immune/inflammatory cells, mesenchymal cells, vascular structures, and extracellular matrix (ECM); 
Figure 2). Intratumor heterogeneity is assumed to occur randomly, but some factors like topography Int. J. Mol. Sci. 2012, 13 1955 
 
 
control the segregation of tumor cells within neoplasms [8–10]. The topographic intratumor 
heterogeneity suggests a differential selection of tumor cells, but can also be expression of either 
selective clonal evolution or a simple passive byproduct of genetic instability [11]. The differential 
kinetic profile by topographic compartments has been related with lower cell turnover and apoptosis 
down-regulation in deep/peripheral compartments, resulting in accumulation of genetic alterations and 
segregation of tumor cells with differential genetic backgrounds as demonstrated in the adrenal gland, 
colon and bladder. This process has been linked with mismatch repair protein down-regulation and it is 
unlikely to be related with hypoxia, which is more pronounced in central compartments. However, the 
coexistence of genetic alterations supports a key role in tumorigenesis, the topographic heterogeneity 
resulting from the accumulation of genetic damage. This concept is central and supports multiple 
sampling to reliably assess the genetic abnormalities of neoplasms. Tumor development can be 
regarded as a process of cell selection. Indeed, large numbers of cell divisions are required for the 
emergence of full-blown malignancies and increased genetic instability, presenting plenty of 
opportunities for the emergence of multiple mutants. This genetic heterogeneity translates into 
phenotypic heterogeneity, and heritable phenotypes will in turn provide material for selection forces to 
work on. However, it is likely that a substantial fraction of phenotypic heterogeneity seen in tumors 
can arise from phenotypic plasticity and differentiation of cancer stem cells (CSC) and is therefore 
non-heritable. 
The heterotypic biology of neoplasms is an essential element to understand tumor growth. The 
underlying defect (clonal genetic alteration) may reside in stromal and not tumor cells, as reported in 
juvenile polyposis syndrome and ulcerative colitis hamartomatous polyps [12]. This finding suggests 
that, at least initially, the stromal cells are the neoplastic cells whose secreting factors drive the epithelial 
proliferation, and might thus eventually also be responsible for the induction of epithelial malignancy. 
This bystander role, mutations inducing stromal abnormalities that in turn induce epithelial neoplasia, 
has been called a landscaper effect: the microenvironment surrounding epithelial cells as a major 
determinant of the disturbed epithelial architecture, differentiation, and proliferation.  
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Figure 2. Heterotypic cell biology of tumors and microenvironment. Distinct cell types 
constitute most solid tumors for both tumor parenchyma and stroma that collectively 
enable tumor growth and progression. Cancer cells (CC) comprise clones with differential 
capabilities for kinetics (proliferating and arrested CC), invasiveness (invasive CC) and 
stemness features (cancer stem cells, CSC). Tumor stroma includes tumor associated 
mesenchymal cells and fibroblasts, tumor-promoting inflammatory cells, marrow-derived 
suppressor cells (MDSC) and the vascular component (endothelial cells and pericytes). The 
multiple stromal cell types create a succession of tumor microenvironments that change as 
tumors invade normal tissue and thereafter seed and colonize distant tissues. The 
abundance, histologic organization, and phenotypic characteristics of the stromal cell types, 
as well as of the extracellular matrix (ECM), evolve during progression, thereby enabling 
primary, invasive, and then metastatic growth. The assembly and collective contributions 
of the assorted cell types constituting the tumor microenvironment are orchestrated and 
maintained by reciprocal heterotypic signaling interactions, of which only a few are 
illustrated. The signaling depicted within the tumor microenvironment is not static but 
instead changes during tumor progression as a result of reciprocal signaling interactions 
between cancer cells and stromal cells that convey the increasingly aggressive phenotypes 
that underlie growth, dormancy, invasion, and metastatic dissemination. Importantly, the 
predisposition to spawn metastatic lesions can begin early, being influenced by the 
differentiation program of the normal cell-of-origin or by initiating oncogenic lesions. 
Cancer stem cells may be variably involved in some or all of the different stages of 
primary tumorigenesis and metastasis. 
 Int. J. Mol. Sci. 2012, 13 1957 
 
 
2.1. Clonal Origin and Expansions. Role in the Natural History of Neoplasms, Tumor Progression, 
and Intra-Tumor Clonal Diversity 
The existence of clonal heterogeneity has been documented for a variety of malignancies, but due to 
multiple technical challenges, the available data are mostly fragmentary, with the extent of clonal 
heterogeneity and the dependence of clonal heterogeneity on tumor type, subtype, and disease stage 
remaining mostly unexplored. It is useful to distinguish cellular genetic heterogeneity (differences at 
the level of single tumor cells) from clonal genetic heterogeneity (differences that have been amplified 
by clonal expansion) [13]. Focusing on clonal heterogeneity instead of cellular heterogeneity 
eliminates some of the “noise” of tumor evolution, as many of the variants detectable at the level of 
individual cells fail to clonally expand because of their occurrence in a cell that has lost stem cell 
properties, unfavorable effects on fitness, or simple stochastic reasons. However, “clonal heterogeneity” 
will not necessarily be completely “noise-free”, as clonal expansion does not necessarily prove the 
selective value of a mutation. 
Neoplasms are not static entities: they start from a genetically normal cell and conclude with 
billions of malignant cells that have accumulated large numbers of mutations during tumorigenesis, 
including the emergence of positively selected mutations (“drivers”) and the accumulation of neutral 
variation (“passengers”) [14,15]. Clonality is a key concept for our current understanding of tumor 
biology and comprises both clonal origin and expansions, which contribute to both tumor initiation and 
promotion [16–19]. Clonality tests cannot be interpreted in isolation; they will be meaningless without 
knowing the effect of a particular marker on cellular kinetics and the interrelationships of that marker 
with other genetic alterations that are present in a given neoplasm. This dynamic aspect is essential to 
get robust results and to avoid misinterpretations that might devalue the findings. As with many other 
issues in tumor biology, it cannot be based on single markers. A complementary approach that takes 
into consideration the technical limitations is essential to avoid the problems. Several markers have been 
used to assess tumor clonality [17,18,20], including X-chromosome inactivation, loss of heterozygosity 
(in particular targeting polymorphic regions of tumor suppressor genes), and mutation analysis.  
The value and information provided by clonality markers must be interpreted in the context of the 
natural history of neoplasms, the scientific methods for test analysis and the test limitations. Neoplastic 
cells reveal genetic alterations that explain the acquisition of autonomous growth (advantageous cell 
kinetics) and invasion capacity (local and distant), most of them acquired. This constellation of 
alterations is most likely related with multiple cooperative genetic abnormalities that explain the 
biologic and clinical progression [4,5]. In this scenario, we need to consider that the first genetic 
alteration has not to be necessarily the irreversible abnormality leading to a clinically detectable 
neoplasm, because genetic alterations can link to apoptosis or may be counterbalanced by other genetic 
changes resulting in no clinical growth. In inherited cancer syndromes, the first genetic alteration is 
known, but on its own does not explain clonal growth, the neoplastic lesion displaying additional 
alterations that correlate with the clinical presentation [17,18]. There are also genetic alterations such 
as fusion genes described in neoplasms and thought to be an initiating event, also present in 
inflammatory conditions. In these circumstances, the evaluation will depend on the agreed definition of 
a given neoplasm [21]. The common finding in all these scenarios is that knowing the first genetic 
event does not guarantee a clonal growth, unless the additional collaborative alterations support an Int. J. Mol. Sci. 2012, 13 1958 
 
 
advantageous cell kinetic resulting in a neoplasm [8,9,19,22–25]. For these reasons a robust clonality 
test must consider evaluating multiple markers that together can support or refuse a common progenitor 
for the lesion. 
The scientific method to analyze clonality must take into account many unknown variables. 
Neoplasms progress through a multistep process in which they acquire genetic abnormalities, but the 
number of genetic alterations, and the sequence of these alterations, is not known [4,5]. It should also 
be noted that, from a perspective of selection operating in the evolution of tumors, stable, heritable 
changes in gene expression due to epigenetic alterations are indistinguishable from similar changes 
caused by alterations in DNA sequences. Silencing of gene expression by hypermethylation of 
promoter regions is frequently observed in cancers [26,27]; therefore, heritable epigenetic changes 
should be included in considerations of clonal evolution. In frequent neoplasms, we know the most 
frequent sequence of genetic abnormalities, but this is not going to be the necessary pathway for all 
neoplasms in a particular location. Considering all these “uncertainties”, the most sensible approach 
will be the statistical one by testing the so-called null hypothesis. In clonality analyses, the null 
hypothesis to test will be if the samples are different, in other words if they come from different 
progenitors. This hypothesis does not assure that the samples are identical or are derived from the same 
progenitor. The strength of the analysis will depend on the number of markers tested and the 
percentage of informative cases for each marker in a normal sample. The higher the values for these 
two parameters, the more reliable are the results obtained. Testing pathway-independent and dependent 
markers would be the most sensible approach for clonality assays, including those contributing to the 
acquired capabilities and processes already identified in neoplasms [4,5]. In that sense, clonality assays 
must fulfill as much as possible the general requirements for any ideal molecular marker [4,5]. Partial 
approaches are valid, but they will not provide the same strength. 
As with any other technique, clonality assays have limitations. The main limitations would be the 
heterotypic biology of solid tumors (tumor and nontumor cells coexisting in the neoplasm and the 
biologic heterogeneity as a byproduct of tumor progression) and the technical aspect to prevent   
artifacts [4,28,29]. The dynamic nature of neoplasms must be taken into account; there is a continuous 
selection process of tumor cells that contributes to biologic progression and results in segregation of 
genetic abnormalities by conditions or topography [10,23–25,30]. Detailed sampling protocols to 
consider predictable heterogeneity (such as the topographic heterogeneity) and protocols including 
quality controls for relevant steps during the tests are absolute requirements to have robust   
results [17,18,28].  
2.1.1. Early Neoplasms, Precancerous Lesions and Progression 
Different types of “precancerous” or “premalignant” lesions are often used inappropriately; in fact, 
many of those lesions “are not pre-anything”. Four types of lesions based on their fate can be 
considered: (I) those that progress to more advanced stages, including cancer; (II) those that continue 
to grow without qualitative change; (III) those persisting with no or minimal growth and no qualitative 
change; (IV) those that may regress. Alternative pathways of progression from intraepithelial 
neoplasms must be considered to understand tumor natural history. Tumor heterogeneity and fully 
established genetic and kinetic features of malignancy in intraepithelial neoplasms and topographic Int. J. Mol. Sci. 2012, 13 1959 
 
 
compartments of invasive malignancies are key factors for this process. These two concepts are closely 
related with tumor initiation, have been developed for epithelial neoplasms and corroborate the concept 
of multistep tumorigenesis and accumulation of cooperative genetic abnormalities (“gatekeeper” and 
“caretaker” pathways) [7]. The paradigm is the concept of intraepithelial neoplasm/malignancy, being 
more difficult to extrapolate the concept to non-epithelial lesions. These lesions would be meaningful 
when they are present in structures with anatomical boundaries and the cells do not recirculate/migrate 
in physiologic conditions, regardless of the lesion size. Regarding anatomical considerations, it is the 
basement membrane, and not the tumor capsule, the limiting structure.  
Although some genetic alterations have been proposed as neoplasm-specific, the presence of a 
single genetic alteration cannot be considered diagnostic of malignancy even for early stages. These 
problems preclude establishing reliable diagnoses of follicular carcinomas in situ for encapsulated 
neoplasms carrying PAX8/PPAR fusion genes, or lymphomas in situ, even for lesions that initially 
carry molecular changes reported in malignancy. The opposite situation is equally important: 
Histologically confirmed intraepithelial lesions are considered precursors, but they can accumulate 
genetic alterations and show kinetic features of malignancies, as reported in MEN 2A [25,31].  
Although the existence of intra-tumor phenotypic heterogeneity has been recognized from the early 
days of experimental cancer research, the relative contributions of heritable and non-heritable 
mechanisms are still not clear, and yet the nature of tumor heterogeneity can have profound implications 
both for tumor development and therapeutic outcomes. Tumor evolution has often been depicted as 
successions of initiations and promotions of mutated cells in clonal expansion rounds, where every 
new round is driven by the acquisition of additional kinetically-advantageous mutational events 
(selection process) [19]. This sequential process of stochastic acquisition of key mutations drives 
tumor progression, as a result of proliferation and increased genomic instability that produce 
progressive selection [9,10,30,32]. Only minority of random mutations are selectively advantageous, 
while a large fraction of mutations will be discarded by selection. Furthermore, many neutral or even 
mildly disadvantageous mutations can be retained in the population or even undergo some expansion 
due to genetic drift. Moreover, the long-term evolutionary success of mutations providing a positive 
selective advantage is not granted. As a consequence, some of the mutations that are selectively 
advantageous at certain stages of tumor progression and can trigger substantial clonal expansion may 
lead to evolutionary dead ends and, therefore, may not be present in a fully malignant tumor. The 
complexity of tumor evolution is further influenced by the ongoing alterations of tumor microenvironment 
associated with tumor progression,[33] which are likely to alter the selective pressures experienced by 
tumor cells. Therefore, at the microscopic level, tumor evolution is likely to be non-linear, and 
substantial genetic heterogeneity is expected in tumor cell populations [10,23,30,31,34].  
2.2. Cancer Stem Cells and Plasticity 
It is important to stress that the concepts of clonal evolution and CSCs are complementary rather 
than mutually exclusive. Tumor progression is contingent on acquiring specific heritable mutations in 
oncogenes, tumor suppressor genes and genome maintenance genes. These genetic alterations must 
target cells with the unique ability to both limitless self-renewal and multipotential differentiation to 
explain tumor growth and progression. As cells with these unique features, the so-called “CSCs”, Int. J. Mol. Sci. 2012, 13 1960 
 
 
represent only a minor fraction of tumor cells, the majority of tumor cells are considered to be products 
of abnormal differentiation of CSCs, and, although some might be capable of limited proliferation, 
they represent evolutionary “dead ends.” From an evolutionary perspective, limitation of self-replicating 
capacity to a fraction of tumor cells means that the effective population size is restricted to this   
stem-like compartment, rather than encompassing a bulk of tumor cells. The implication is that 
phenotypic and genetic heterogeneity, associated with tumor stem cell differentiation, are irrelevant for 
tumor progression (as long as they do not affect the tumor stem cell subpopulation or lead to stem cell 
conversion), as selection can only work on the heritable phenotypes of CSCs (Figure 2). 
In recent years, evidence accumulated suggesting that a small tumor cell subpopulation in the 
primary tumor mass might be responsible for tumor initiation, growth, maintenance and spreading. 
These cells, termed CSCs or cancer initiating cells (CSC/CIC), represent a population with stem   
cell-like properties, in particular long-term survival, high self-renewal and seeding capacities [35]. 
While the cellular origin of CSC/CIC and the associated molecular pathways are still a matter of 
discussion, the existence of a small tumor cell subpopulation capable of initiating and maintaining 
tumor growth and initiating metastasis is being increasingly documented and accepted [36,37]. 
Furthermore, evidence indicates that CSC/CICs are more resistant to classical therapeutic approaches 
(i.e., chemotherapy and radiotherapy) compared to the bulk of the tumor cell mass. The mechanism  
of resistance remains largely elusive and might include the increased expression of multi-drug   
resistance-type of membrane transporters, a protective effect of the microenvironment or especial 
resistance to apoptosis. The existence of morphologically defined subsets of cancer cells, which are 
enriched with the ability to form tumors in xenograft models, has been demonstrated for many 
hematopoietic and solid malignancies. Initial evidence for the existence of CSC/CIC came from acute 
myeloid leukemia rare leukemic (stem) cells with a CD34
+/CD38
− phenotype, and subsequently 
demonstrated in solid tumors, but with different surface phenotype [38,39]. In all cases, CSC/CIC is 
distinguished from the “somatic” tumor cell population, by their capacity to efficiently generate new 
tumors when implanted at low number in mice. Conversely, “somatic” cancer cells are not able to 
initiate tumor growth, even in high number, in the same in vivo preclinical models. A major challenge 
to the CSC concept originates from the observation that its definition is based on experimental 
evidence (e.g., tumor initiation at limited dilution) that is highly subject to how the assay was 
performed. For example, in experimentally induced or spontaneous cancers, the majority of cancer 
cells are capable of initiating tumors in either syngenic or xenograft models [40], and thus can be 
considered CSCs. When most of the cells in a tumor are CSCs, singling them out becomes meaningless. 
It has also been noted that numerical considerations frequently reveal inconsistencies with data 
interpretation in experiments transplanting sorted cell populations [41]. In addition, comparisons of the 
genetic composition of breast cancer CD44
+CD24
− cells, which are presumed to be “CSCs”, versus 
CD44
−CD24
+ cells, which are considered to be “non-stem cells”, have revealed that in some cases 
these subpopulations are genetically divergent [42,43], which is inconsistent with a model of   
simple differentiation. 
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2.2.1. Phenotypic Plasticity 
Tumor cell plasticity explains the differential ability of specific subsets of tumor cells to initiate 
tumors in experimental models. This hypothesis proposes that the majority of tumor cells reveals stem 
cell features with varying degrees of “stemness”, where the “stemness” is influenced by microenvironmental 
cues and some stochastic cell-autonomous mechanisms [44]. Observation of substantial phenotypic 
and functional heterogeneity within normal stem/progenitor cell pools has led to organizational models 
of stem cell compartments that incorporate self-organization, flexibility, and plasticity of stem cell 
properties [45–47]. Importantly, mathematical models that involve plasticity of the stem cell 
phenotype provide a much better match to experimental data on stem cell dynamics than does the 
concept of rigid differentiation hierarchy [14,41,48]. Concepts of CSCs and phenotypic plasticity are 
not mutually exclusive. Even if the majority of tumor cells in some (or many) cancers are incapable of 
sustained proliferation and, therefore, can be described as non-stem cells, the stem cell compartment 
can still be phenotypically diverse and plastic. Regardless of the outcome of the CSC debate, it is 
likely that non-heritable mechanisms are responsible for a large fraction of intra-tumor heterogeneity 
of cellular phenotypes. 
Genotypes specify a range of phenotypic manifestations within a norm of reaction. This concept 
would explain the tumor cell ability of altering their phenotype in response to microenvironmental 
cues and, as a result of this tumor cell-microenvironment interaction, the tumor behavior and 
progression are shaped. However, the tumor microenvironment is not completely homogeneous: 
different regions of a tumor can have different densities of blood and lymphatic vasculature, different 
numbers and types of infiltrating normal cells, and different composition of ECM. Therefore, tumor 
cells within a given tumor are expected to experience a range of microenvironmental cues, which 
would translate into a range of phenotypic manifestations. In addition, cells can show heterogeneity of 
features even within apparently homogeneous environments. Such heterogeneity arises from noise in 
gene expression and existence of meta-stable configuration of intracellular networks, and it is a very 
basic feature of all living cells. Normal and cancer cell lines display substantial heterogeneity in timing 
of apoptotic response to TRAIL ligand. This heterogeneity does not depend on genetic or epigenetic 
mechanisms but is instead caused by apparently noise-driven differences in levels of protein 
expression [49]. Plasticity of tumor cell phenotype is not limited to apoptotic response. For example, 
genetically homogeneous tumor cell lines display morphological heterogeneity, as mixtures of 
immotile, rounded cells and motile, fibroblast-like ones can be found both in vitro and in vivo. In this 
case, the phenotypic differences result from different, mutually exclusive, and inter-convertible 
activation of Rac and Rho GTPases [50].  
2.3. Interactions of Distinct Tumor Clones. Clonal Evolution and Progression 
Two main mechanisms explain the impact of clonal heterogeneity on tumor evolution, modulating 
both progression and therapeutic escape: (a) Clonal diversity provides a more diverse genetic spectrum 
on which selection can take place; (b) The co-existence of genetically distinct clones within a tumor 
gives a network of biological interactions among distinct clones. As a consequence, the behavior of a Int. J. Mol. Sci. 2012, 13 1962 
 
 
tumor composed of distinct clones might be different from that of a monoclonal tumor or the behavior 
of the sum of the individual clones [15,33]. 
2.3.1. Tumor Evolution as Byproduct of Clonal Heterogeneity 
Tumorigenesis is a dynamic selective process driven by genetic changes (mutations in broader 
terms) and abnormal gene expression [51]. In this context, higher genetic complexity is expected to 
provide more options for selection and a faster pace of evolution in heterogeneous neoplasms. As 
tumors grow, the cellular stress derived from replication results in mutations and expansion of   
sub-clones from the branching of the original precursor (monoclonal population). This selection results 
in an increased genetic complexity generated by branching from a tumor composed of multiple distinct 
clones. Thus, clonally heterogeneous tumors can generate a larger variety of genetic variants to be 
tested by selection, which provide a wider adaptive landscape, increasing the probability of clones 
reaching fitness for challenges from several microenvironments (Figure 2).  
The clonal composition of tumors can be especially important in determining responses to dramatic 
changes in the environment, such as changes induced by anti-cancer therapy. In this case, the   
pre-existence of resistant clones within a tumor can make the difference between tumor extinction 
(treatment success) and tumor evolutionary adaptation (treatment failure). A vivid illustration of the 
importance of clonal heterogeneity in therapeutic resistance can be found in malignancies such as 
chronic myelogenous leukemia [52], gastrointestinal stromal tumors (predominantly driven by different 
activating mutations in KIT) [53], tumors associated with inactivating mutations in BRCA1 and 
BRCA2 (deficient in homologous recombination-mediated DNA repair resulting in genomic instability 
and highly sensitive to platinum compounds and poly ADP ribose polymerase inhibitors) [54], just to 
give some examples. For many tumors with genetic mechanisms of resistance pre-existence of 
resistant cell types prior to treatment has yet to be demonstrated. Moreover, the generality of the 
mutational mechanisms of acquiring therapeutic resistance remains an open question [55]. Nonetheless, 
intra-tumor heterogeneity is likely to represent a strong challenge to therapeutic success, as larger 
genetic diversity within a tumor would be expected to increase the probability of the pre-existence of 
resistant cell types that could be selected by treatment and ultimately result in relapse of resistant 
tumors. Notably, in addition to the scenario of cancer therapy, selection of mutant variants rather than 
mutagenesis was proposed to be the key mechanism responsible for the carcinogenic action of a wide 
range of growth-limiting carcinogens [55–57].  
2.3.2. Biological Interactions among Distinct Tumor Clones 
Cancer morphologic and genetic heterogeneity is the expression of multistep tumorigenesis that 
leads to subclonal tumor cell populations with heritable traits (including primary, circulating and 
metastatic cells) and a microenvironment of ECM, fibroblasts, inflammatory cells and blood vessels. 
In addition, the differentiation hierarchy within tumors complicates the network, along with the 
importance of tumor microenvironment, as it is increasingly clear that understanding alterations within 
tumor cells is only part of the picture, and we need to understand interactions between tumors and  
their microenvironment to account for multiple aspects of tumor progression and therapeutic   
resilience [33,58,59]. A major implication is the co-existence of phenotypically distinct clonal Int. J. Mol. Sci. 2012, 13 1963 
 
 
populations of tumor cells should inevitably lead to the formation of a network of biological 
interactions, which could be either direct or mediated by the tumor microenvironment. Some of the key 
interactions that are likely to exist between distinct tumor clones are summarized below   
(Figure 3) [60]. 
Figure 3. Interaction between tumor cell clones. This process includes competition, 
amensalism, commensalism, mutualism, parasitism and predation; the outcome is a higher 
level of complexity of tumor heterogeneity at the cellular level.  
 
Competition is likely to be the strongest and most important biological interaction between tumor 
cells and it is one of the mechanisms involved in the tumor response to irradiation [61]. Mechanisms to 
limit the competitive outgrowth of mutant cells include intrinsic tumor-suppressive mechanisms, 
wherein activation of strong oncogenes triggers activation of tumor-suppressive networks, resulting in 
senescence or death of mutated cells [62]; or oncogenic mutations that can trigger stronger 
proliferation without engaging intracellular tumor suppressors resulting in loss of stemness (extrinsic 
tumor suppressor mechanisms) [63]. Moreover, the spatial organization of normal tissues can limit the 
role of competition between genetically distinct cells even further, confining stem cells to small   
pools [64,65]. However, carcinogenic and growth-limiting conditions can substantially modify the 
fitness landscape, allowing for the competitive outgrowth of oncogenically mutated cells, thereby 
initiating malignant evolution [66,67]. Tumor progression is associated with further loss of   
tumor-suppressive mechanisms and disintegration of normal tissue morphology; thus, tumors start to 
resemble ecological systems rather than integrated tissues, and competition becomes the strongest 
biological interaction. The role of competition is further strengthened by the limited nature of Int. J. Mol. Sci. 2012, 13 1964 
 
 
resources: while, under tissue culture conditions, tumor cells are capable of limitless exponential 
growth, clonal expansion within tumors is severely constrained by the limited availability of oxygen, 
nutrients, growth factors, and space (habitable niches). Limited resources intensify competitive 
interactions both within and between interacting species (cancer subclones). In large, spatially 
homogeneous populations, competitive interaction results in the fixation of a clone with the highest 
fitness value [60,64,65]. However, as discussed above, fixation can be inhibited by spatial organization, 
which limits competition to within clones. In addition, the existence of regions with different selective 
pressures can mediate the co-existence of clonally distinct populations. Finally, a stable co-existence of 
multiple clones is also possible when fitness is density-dependent [68].  
Amensalism is an interaction in which one interacting party is inhibited by the other without being 
affected itself. Under the competitive context, this interaction is also referred to as “interference 
competition”. As tumors grow under conditions of limited resources, amensalistic interactions can 
provide a competitive advantage to a clone that can inhibit other clones while being (at least relatively) 
resistant. An example of this type of interaction between genetically distinct human cells can be found 
in Bcr-Abl-driven leukemias [69]. The existence of this type of interaction has also been documented 
among distinct tumor clonal populations, both in cell culture and in vivo. The concept of amensalism 
can be extended to interactions between primary and metastatic tumors, as many human and experimental 
tumors can suppress metastatic outgrowth by inhibiting angiogenesis or inducing dormancy of single 
disseminated tumor cells through uncharacterized mechanisms [70]. Thus, amensalism can work as a 
weapon in competitive “warfare” between distinct clonal populations, which can lead to the stable  
co-existence of distinct clones in tumors.  
Antagonism is an interaction in which one interacting party can capture biomass from the other one. 
This interaction is widespread in natural ecosystems, and there are clear parallels between   
organism–tumor and host–parasite interactions. However, antagonism is unlikely to be relevant for the 
interactions between distinct tumor clones. 
Commensalism is a positive interaction in which one interacting party benefits the other without 
itself being affected. The tumor cell-stromal cell interaction in itself is a form of commensalism, 
because it has been demonstrated that these non-malignant cells support and even enable tumor   
growth [71]. An example of this type of interaction can be found in normal tissues: mammary 
epithelial cells from estrogen receptor null mice (ERα-/-) fail to grow and do not develop branching 
structures upon transplantation into cleared fat pads. However, when mixed with wild-type epithelial 
progenitors, ERα-/- cells do proliferate and contribute to different lineages and different parts of the 
mammary gland [72]. In addition, nearby cells can protect each other from a set of host defenses that 
neither could survive alone. Cooperation can evolve as by-product mutualism among genetically 
diverse tumor cells [71]. A recent publication from the Weinberg laboratory demonstrated the relevance 
of this interaction in a human xenograft model, where an “instigator” tumor cell line augmented the 
proliferation and metastasis of genetically distinct “indolent” tumors that were incapable of forming 
macroscopic outgrowths on their own [73,74]. In this case, the “instigation” was mediated by systemic 
effects, which could at least partially be attributed to the secretion of SPP1 (osteopontin) by the 
“instigator” cells [74].  
Although not experimentally validated, this interaction can account for the co-existence of clonal 
variants that differ in their angiogenic potential. If the fitness benefit of angiogenic factor production is Int. J. Mol. Sci. 2012, 13 1965 
 
 
higher than the associated fitness cost, an angiogenic clone can undergo competitive expansion and 
reach stable equilibrium with non-angiogenic “free rider” clones. Interestingly, mathematical modeling 
shows that, under certain physiologic conditions, “free riders” capable of faster proliferation can   
out-compete the angiogenic clone, leading to the collapse of the tumor [68]. This prediction can 
potentially explain spontaneous regression of neuroblastomas accompanied by massive necrosis [75].  
Mutualism (cooperation) is a positive interaction in which both interacting parties can benefit from 
each other. Positive interactions between species have been widely documented in natural ecosystems. 
Mathematical modeling suggests that mutualistic interactions can lead to the co-existence of distinct 
species even under competitive contexts [71,76]. It has been suggested that mutualistic interactions 
between distinct tumor clones can play an important role in tumor evolution by maintaining the 
survival and proliferation of tumor cells until one of the clones achieves a “full deck” of malignant 
mutations required for clonal dominance and full-blown malignancy [71,77]. To the best of our 
knowledge, however, such interactions between distinct clonal tumor populations have not been 
experimentally documented. 
Of note, most of the biological interactions are not mutually exclusive, and the net outcome for the 
interacting species will depend on the net sum of the different interactions (Figure 3). This net result 
can lead to both augmentation and retardation of overall tumor growth and progression. Elucidation of 
biological interactions between populations of tumor cells might be a very formidable task; however, it 
can deepen our understanding of tumor biology and uncover new therapeutic targets. 
3. Tumor Components 
Normal cells survive and grow within defined environmental niches and are subjected to 
microenvironmental control. Outside of their specific niche, the tissue environment is hostile to normal 
cells. Since they lack necessary cell autonomous survival signals, normal cells will not survive an 
inappropriate microenvironment [78]. Detachment-induced cell death (anoikis) has been proposed as 
the mechanism preventing normal cells from leaving their original environment and seeding at 
inappropriate locations [4]. In order to evade local tissue control and avoid anoikis during tumor 
development and progression, malignant cells start interacting with the surrounding ECM [79]. A 
bidirectional relationship is initiated between tumor cells and its surrounding stroma as a first step to 
invasive growth on metastatic spreading. Stromal changes sustaining tumor progression include 
modifications of the ECM composition, activation of fibroblasts, myoepithelial cells, and the 
recruitment of pericytes or smooth muscle cells and immune and inflammatory cells [80].  
3.1. Cellular Interactions and Microenvironment 
Human tumors arise from single cells that have accumulated the necessary number and types of 
heritable alterations. Each such cell leads to dysregulated growth and eventually the formation of a 
tumor. Despite their monoclonal origin, at the time of diagnosis most tumors show a striking amount 
of intratumor heterogeneity in all measurable phenotypes; the evolutionary dynamics of heterogeneity 
arising during exponential expansion of a tumor cell population, in which heritable alterations confer 
random fitness changes to cells [48]. Classical multistage modeling of tumorigenesis evolves through 
the processes of local proliferative lesions (tumor initiation and promotion or selection), and acquisition Int. J. Mol. Sci. 2012, 13 1966 
 
 
of invasion-metastatic potential (tumor progression). Broadly speaking, tumor promotion consists of 
the selective (clonal) expansion of altered cells to form focal lesions [16,81]. Within this definition, the 
process of promotion is mainly a quantitative phenomenon (many cells arising from a single cell), 
while no qualitative changes are necessarily implied. However, these latter properties are lost during 
tumor progression, which is typically characterized by increasing levels of tumor cell heterogeneity. 
This implies that qualitative changes are now dominant [18,19], generating distinct cellular sub-clones 
with different phenotypes. Such a background represents the landscape for the full deployment of 
tumor progression. 
These two distinctive processes, the mainly quantitative process of tumor promotion and the 
intrinsically qualitative process of tumor progression, are driven by two distinct microenvironments: 
the tissue and the tumor microenvironments [56,57,82]. The tissue microenvironment specifically 
refers to the local environment surrounding altered cells during their selective clonal expansion to form 
focal proliferative lesions. Conversely, the tumor microenvironment describes the unique biological 
milieu that emerges inside focal proliferative lesions as a consequence of their altered growth   
pattern [56,57,82]. Such new biological niche is characterized by a tissue architecture which is not 
developmentally programmed and is bound to pose major challenges for  cell survival, due to 
altered/inadequate supply of oxygen and nutrients. This in turn can lead to biochemical and metabolic 
alterations that can profoundly impact on the fate of the cell populations inside focal lesions [83].  
The available evidence is consistent with the hypothesis that focal lesions result from the clonal 
expansion of altered cells; if so, how does a focal lesion develop from those rare altered cells? 
Theoretically, at least two different (and not mutually exclusive) possibilities should be considered: 
(I) The altered/initiated cell is already endowed with some degree of inherent growth autonomy and 
starts to replicate unchecked, forming a focal lesion and then, after a number of further steps, a full 
blown cancer [84]. The analysis of several multistage models of cancer induction has led to the 
conclusion that initiation per se does not result in any significant growth of pre-neoplastic and/or 
neoplastic lesions, and the appearance of the latter is heavily dependent on the presence of a 
promoting/selective environment [85]. Furthermore, transplantation experiments have convincingly 
demonstrated that different types of altered cells do not display any evidence of growth autonomy 
when transferred in a normal tissue environment of young animals in vivo [67]. By analogy, altered, 
putative initiated cells can be found in the skin of several healthy human subjects, suggesting that their 
presence per se is not necessarily associated with selective clonal growth, and additional 
(promoting/selective) influences must be enforced when the latter does occur [86]. Also epidemiologic 
evidence on smoking and lung cancer suggests that clonal expansion of cells is much more relevant 
than early mutations [87].  
(II) The other possibility is that the single altered cell does not express any significant degree of 
growth autonomy and is still under the control of normal homeostatic mechanisms; if this is the case, 
its selective clonal growth must be linked to the dynamics of cell turnover typical of the tissue where it 
resides. Thus, specific alterations of these dynamics could translate into a promoting effect for any 
putative altered cells present in that tissue. It is self-apparent that, within this perspective, the tissue 
microenvironment surrounding rare initiated/altered cells is given a central role in their selective 
emergence as focal proliferative lesions. In this context the neoplastic development is a biologic Int. J. Mol. Sci. 2012, 13 1967 
 
 
process that is not directly caused by the inciting agent acting on a passive target, but results from the 
interaction of living structures (cells, tissues and organs) with those agents [88,89].  
A direct link was established between growth inhibitory effects and the emergence of 
phenotypically resistant cell populations during carcinogenesis. Rare initiated cells could withstand 
certain types of growth suppression imposed on surrounding normal cells, thereby acquiring a 
proliferative advantage under appropriate “selective” conditions. Furthermore, the growth of such 
resistant cells to form focal proliferative lesions could be induced by physiological homeostatic stimuli, 
as it occurs during tissue regeneration and/or turnover, and these rare clones could emerge because the 
bulk of surrounding normal cells were unable to respond to those stimuli [90]. Incidentally, the work 
of Farber was the first to provide evidence that tumor promotion could be interpreted (and in fact 
defined) as a process of cell selection, thereby introducing a Darwinian perspective in the analysis of 
carcinogenesis [91]. Thus, early phases of cancer development, far from being exclusively cell-
autonomous, appeared to be heavily dependent on environmental influences and in fact could be 
interpreted as adaptive reactions to altered conditions in the surrounding tissue [88]. Specifically, if the 
growth potential of normal cells in a given tissue was severely impaired, this could translate into a 
driving force for any altered/initiated cells to expand and compensate for the (relative) impairment of 
their surrounding counterparts. As a consequence, cancer development is a process to be considered 
and analyzed at tissue/organ level, not just at single cell level, and a role for the tissue 
microenvironment in this process is clearly defined [12,88,92]. 
3.1.1. Promoting Potential of a Growth-Constrained Tissue Microenvironment 
As the large majority of carcinogens can both (I) exert growth-suppression in the target tissue, 
possibly as a consequence of the inflicted DNA-damage [93], and (II) induce rare altered/initiated cells 
with a resistant phenotype [94], a clear outcome of such combined effects includes the possibility of a 
selective expansion of the resistant cell population [91,93]. Given that random mutations are more 
likely to damage the function of the genome rather than to improve it [91], the same genotoxic agent 
can both initiate the carcinogenic process in a given tissue and exert a promoting/selective effect on 
rare initiated/altered cells by limiting the proliferative potential and/or impose other cytotoxic effects 
in the bulk of the surrounding cells in that tissue [95]. 
A direct testing of the hypothesis that a growth-constrained microenvironment can represent a 
powerful driving force during tumor promotion is provided by cell transplantation experiments. Under 
growth-constraint endogenous conditions, transplanted altered cells could selectively expand in the 
recipient liver, forming hepatocyte nodules and eventually progressing to hepatocellular carcinoma. 
Importantly, no nodular growth was observed when a similar preparation of hepatocytes was injected 
into normal, untreated recipients [67], suggesting that nodular cells had no inherent growth autonomy: 
the selective growth of altered cells in this system occurs under the influence of homeostatic mechanisms 
which are similar to, and possibly coincide with those controlling normal cell turnover [96]. 
One relevant situation to be considered in this context is aging. In fact, aging represents the major 
risk factor for neoplastic disease (albeit it is not an avoidable risk) [97]; moreover, it is characterized, if 
not defined, by a generalized decrease in the functional proficiency of several organs and tissues, 
including a decline in their proliferative potential [98]. It has been shown that the microenvironment of Int. J. Mol. Sci. 2012, 13 1968 
 
 
the aged liver is able to support the growth of a transplanted epithelial cell line, while that of the young 
recipient is not [99], being able of stimulating the clonal expansion of transplanted normal   
hepatocytes [100]. This phenomenon does suggest that the liver microenvironment associated with 
aging is also clonogenic, and could therefore foster the emergence of altered cell populations. It 
appears reasonable to propose that such clonogenic potential might be linked, at least in part, to the 
growth-constrained environment associated with aging [100]. It is likely that a role in such   
age-associated clonogenic effect is also played by stromal fibroblasts. Senescent fibroblasts can in fact 
stimulate early growth of both grafted normal and tumor epithelial cells, suggesting that they can mediate, 
at least in part, the effect of aging on the parenchymal component of various tissues [101,102]. However, 
this effect can translate into selective growth of rare altered cells if the majority of surrounding 
counterparts are relatively impaired in their proliferative capacity, as it occurs during aging [103].  
From a more general standing point, chronic tissue injury and inflammation lead to both impaired 
function and an increased risk of neoplastic disease in the target organ [104,105]. It is reasonable to 
consider that a common factor in all these instances could be the progressive exhaustion of the 
functional and/or proliferative capacity of parenchymal cells, paving the way to the selection of rare 
variant cells with an altered phenotype [106]. Consistent with this interpretation is the finding of 
diffuse or focal parenchymal atrophy concomitant with proliferative lesions of putative clonal   
origin [107–111]. The “proliferative inflammatory atrophy” of the prostate has been recognized as a 
risk factor for prostate carcinogenesis and it is characterized by clusters of proliferating prostatic cells 
arising in areas of atrophic epithelium [108], suggesting their possible regenerative significance [109].  
In this context, defects in DNA repair pathways (a known cancer risk) result in increased 
probability of critical genetic alterations occurring in rare cells, and this will lead to the emergence of 
the neoplastic phenotype. However, such interpretation largely overlooks the consequences that the 
defective DNA repair might have on the bulk of the tissue, and their possible contribution to the 
increased carcinogenic risk that is seen in these conditions. Defects in DNA repair pathways can be 
associated with accumulation of widespread DNA damage [112]. It is reasonable to assume that such 
randomly inflicted damage will generally impair genome function [112], rather than improve it; in fact, 
accelerated aging has also been associated with altered DNA repair capacity [113]. Thus, the above 
considerations suggest that carcinogenesis related to defective DNA repair is also interpretable as the 
end result of at least two main biological components: (I) induction of rare altered cells; and 
(II) selection of such cells within a functionally impaired tissue environment. 
3.1.2. Molecular Analysis of Selectogenic Microenvironments 
Given that altered cells can be selected in a tissue microenvironment which is otherwise   
growth-inhibitory to surrounding counterparts, a relevant question pertains to the biochemical and 
molecular basis of such phenotypic resistance. Blagosklonny has proposed the existence of two broad 
types of resistance [55]: (I) Non-oncogenic resistance relates to changes in drug metabolism and/or 
uptake, such that the rare altered cell is able to withstand toxicity compared to the rest of the population 
in that tissue. Such phenotypic resistance would still translate in the clonal growth of that rare cell, but 
no increased risk of neoplastic disease would be implied [55]. (II) The oncogenic resistance is linked to 
the inability of the cell to sense or repair DNA damage and/or to activate effector mechanisms leading Int. J. Mol. Sci. 2012, 13 1969 
 
 
to cell cycle arrest and/or cell death. As a result, the affected cell is susceptible to acquire a “mutator 
phenotype”, i.e., the tendency to undergo a cascade of further mutations [4,8,91,114]. 
The mutator phenotype has been linked with a defect in mismatch repair (MMR) genes, so that a 
cascade of mutations occurs in cancer-related genes. To justify the onset of a mutator phenotype in 
“sporadic cancers” (which are in fact the vast majority) we have to revisit some theories of 
carcinogenesis and their evidence base [10,32]. In sporadic cancers the origin of the mutator phenotype 
has been attributed to chance, or to mutagens that selectively affect specific genes similar to MMR 
genes, or to a combination of the two. However, MMR is clearly mutated only in a minority of cases: 
For example, colon cancers characterized by the presence of microsatellites (MIN) are a small minority 
compared to cancers characterized by chromosome instability (CIN), whose onset has not yet been 
attributed to the failure of any specific gene repair such as MMR [8,114]. To explain the most common 
type of lesions that are found in non-hereditary cancers, chromosome aberrations and CIN, we have to 
explain how the mutator phenotype originates. In addition, a key concept that has also emerged 
recently is that mutations, or instability, are irrelevant if there is not a microenvironmental change that 
selects the cells carrying such mutations. Therefore, we will first discuss some examples of such a 
“selectogenic” microenvironment. 
3.1.3. Stress and the Mutator Phenotype 
Cell replication is the main source of cellular stress. On one hand, continuous proliferation results in 
telomere attrition and reduced stability of chromosome ends, which activate the cycle of chromosomal 
fusion-bridge-breakage and higher incidence of translocations such as expression of chromosomal 
instability (CIN). On the other hand, nucleotide mismatches are introduced by DNA polymerase and 
will accumulate in DNA regions with repetitive sequences, such as microsatellites; this is the basic 
reason of microsatellite instability (MSI), a finding more frequently detected in tissues with higher 
proliferation. CIN and MSI have been described as two alternative pathways to cancer [4,8]. CIN is 
generally defined as the ability of a cell to gain and lose chromosomes and is a feature of many types 
of cancer. Conversely, microsatellite instability is related to a defect in the DNA mismatch repair 
machinery (MSI cancers).  
The net result of CIN is the deregulation of chromosome number (aneuploidy) and an enhanced rate 
of loss of heterozygosity, which is an important mechanism of inactivation of tumor suppressor genes. 
Cytogenetic studies of bladder, lung and colon tumors have shown that karyotype complexity, cell 
ploidy, and the number of structural changes found are closely associated with tumor grade and stage. 
It has been suggested that different environmental carcinogens can induce specific forms of genetic 
instability [115]. The available data demonstrate that exposure to specific carcinogens can indeed 
select for tumor cells with distinct forms of genetic instability and vice versa. These data offer 
potential clues to one of the remaining unsolved problems in cancer research, the relationship between 
environmental factors and the genetic abnormalities that effect tumorigenesis. 
3.1.4. Chronic Inflammation, Myeloid-Derived Cells in Tissue and Tumor Microenvironment 
Chronic inflammation promotes tumor onset and development through nonimmune and immune 
mechanisms. The nonimmune mechanisms include the following: (I) the production of reactive oxygen Int. J. Mol. Sci. 2012, 13 1970 
 
 
species (ROS) such as peroxynitrites, which cause DNA mutations that contribute to genetic instability 
and the proliferation of malignant cells [116]; (II) the production of proangiogenic factors such as 
vascular endothelial growth factor (VEGF), which promote tumor neovascularization [117]; and 
(III) the production of matrix metalloproteases, which facilitate invasion and metastasis [118]. The 
predominant immune mechanism is the perturbation of myelopoiesis and hemopoiesis, which causes a 
deficiency in Ag-presenting dendritic cells (DC) and dysfunctional cell-mediated antitumor   
immunity [119]. A major culprit in this latter deficiency is the production of myeloid-derived 
suppressor cells (MDSC), an immature population of myeloid cells that is present in most cancer 
patients and mice with transplanted or spontaneous tumors. Because MDSC inhibit both innate and 
adaptive immunity, they are likely to subvert immune surveillance and prevent an individual’s immune 
system from eliminating newly transformed cells. In individuals with established cancer, they are 
likely to be a major factor in preventing the efficacy of immunotherapies, such as cancer vaccines, that 
require an immunocompetent host [120,121]. MDSC cause immune suppression in most cancer 
patients, where they are an impediment to all immunotherapies that require an active immune response 
by the host. They may also facilitate the transformation of premalignant cells and promote tumor 
growth and metastasis by suppressing innate and adaptive immune surveillance that would otherwise 
eliminate abnormal cells. The induction of MDSC by proinflammatory factors identifies the immune 
system as another contributing mechanism by which chronic inflammation contributes to the onset and 
progression of cancer.  
In the tumor microenvironment, tumor associated macrophages (TAMs) constitute the majority of 
tumor-infiltrating leukocytes. MDSC have been identified in most patients and experimental mice with 
tumors based on their ability to suppress T cell activation. The nuclear morphology and content of 
immunosuppressive substances have also been used to characterize mouse MDSC. Two distinctive 
TAM sub-populations have been defined. Classical, or M1, macrophages are characterized by the 
expression of high amounts of iNOS and tumor necrosis factor-α (TNF-α), whereas alternatively 
activated M2 macrophages typically produce ARG1 and IL-10 [122,123]. At the tumor site in   
wild-type mice, TAMs are predominantly M2-like macrophages, which are the cells primarily responsible 
for suppressing T cell-mediated antitumor responses and promoting tumor progression, metastasis, and 
angiogenesis [124-126]. M1 macrophages, in contrast, exhibit, a tumoricidal effect [127–129]. 
Monocytic MDSCs and TAMs share several characteristics, such as expression of the monocyte and 
macrophage markers F4/80 and CD115, as well as inducible expression of iNOS and ARG1 [123,124,130]. 
Accumulating evidence suggests that, upon entering tumor tissues, MDSCs may differentiate into 
TAMs, leading to elevated IL-10 production, inhibition of T cell responses, and promotion of 
angiogenesis [131]. However, the mechanism behind regulation of MDSC differentiation remains 
unclear [123,131,132].  
Macrophages within the tumor microenvironment facilitate angiogenesis and extracellular-matrix 
breakdown and remodeling and promote tumor cell motility. There is a direct communication between 
macrophages and tumor cells that lead to invasion and egress of tumor cells into the blood vessels 
(intravasation). Thus, macrophages are at the center of the invasion microenvironment [133]. Mononuclear 
phagocytes are recruited in large numbers as primary monocytes from the circulation to diseased 
tissues, where they accumulate within ischemic/hypoxic sites terminally differentiating into inflammatory 
and tumor-associated macrophages or myeloid DCs. The cytokine MIF is over-expressed in tumors Int. J. Mol. Sci. 2012, 13 1971 
 
 
and is associated with tumor proliferation, angiogenesis and metastasis. Hypoxia, a hallmark feature  
of tumors, increases MIF expression from tumor cells. Inhibition of transcription and translation 
significantly decreased MIF production, suggesting that hypoxia-induced secretion of MIF is via an 
alternative pathway [134]. Hypoxia-mediated changes in mononuclear phagocyte gene expression and 
functional properties under different pathologic situations demonstrate that oxygen availability is a 
critical regulator of their functional behavior. Experimental evidence demonstrating that hypoxia 
modulates in primary monocytes the expression of a selected cluster of chemokine genes with a 
characteristic dichotomy resulting in the up-regulation of those active on neutrophils and the inhibition 
of those predominantly active on monocytes, macrophages, T lymphocytes, NK cells, basophils   
and/or DCs is reported. A negative regulatory role of hypoxia on monocyte migration is exerted 
through several alternative or complementary mechanisms and results in monocyte “trapping” within 
ischemic/hypoxic sites of diseased tissues. Data relative to the ability of hypoxia to differentially 
regulate in immature DCs (iDCs) the expression profile of genes coding for chemokines and 
chemokine receptors, the former being down-regulated and the latter up-regulated, thus promoting the 
switch from a proinflammatory to a migratory phenotype of iDCs by, respectively, reducing their capacity 
to recruit other inflammatory leukocytes and increasing their sensitivity to chemoattractants [135]. A 
partial overlap exists among mononuclear phagocytes at various differentiation stages in the expression 
of a cluster of hypoxia-responsive genes coding for regulators of angiogenesis, proinflammatory 
cytokines/receptors, and inflammatory mediators and implicated in tissue neo-vascularization and cell 
activation. Transcription pathways underlying hypoxia-regulated gene expression in monocytic lineage 
cells support a major role for the hypoxia-inducible factor-1 (HIF-1)/hypoxia responsive element 
(HRE) pathway in monocyte extravasation and migration to hypoxic sites and in the activation of 
monocyte/macrophage proinflammatory and immunoregulatory responses by hypoxia both in vitro and 
in vivo. Recent experimental evidence suggesting the requirement of additional transcription factors, 
such as nuclear factor-kappaB (NF-kappaB), Ets-1, CCAAT/enhancer binding protein-alpha/beta 
(C/EBPalpha/beta), activator-protein-1 (AP-1), and early growth response-1 (Egr-1), for hypoxic 
regulation of gene transcription in primary human monocytes and differentiated macrophages and 
indicative of the existence of both a positive and a negative O(2)-driven HIF-1-dependent feedback 
regulatory mechanism of hypoxia transcriptional response in primary monocytes [135]. 
Whether tumor-induced MDSC are normal cells halted in the intermediate stages of differentiation 
or whether they have diverged from the normal myeloid differentiation pathway and accumulated 
mutations is unclear. Direct comparisons of in vitro suppressive activity of splenic Gr1
+CD11b
+ cells 
from tumor-free mice vs tumor-bearing mice are not consistent. MDSC that are mononuclear are 
considered “monocytic” and typically are CD11b
+Ly6G
+/−Ly6C
high, whereas those with multilobed 
nuclei are “granulocytic/neutrophil-like” and have a CD11b
+Ly6G
+Ly6C
low phenotype [136,137]. 
MDSC also vary in their content of immunosuppressive substances, with different populations 
containing arginase [138,139], inducible NO synthase [140], and/or additional ROS [138,140]. In 
cancer patients MDSC are typically CD11b
+CD33
+CD34
+CD14
−HLA-DR
− and can vary in their 
expression of CD15 and other markers [136,137]. The variation in MDSC phenotype is consistent with 
the concept that MDSC are a diverse family of cells that are in various intermediate stages of myeloid 
cell differentiation. MDSC are driven by tumor-secreted factors, and different tumors secrete different 
combinations of molecules. Therefore, MDSC phenotype will depend on the specific combination of Int. J. Mol. Sci. 2012, 13 1972 
 
 
factors within the tumor host. Because the myeloid population contains many different cell types and 
myeloid cell differentiation is a continuum of processes, MDSC may display diverse phenotypic 
markers that reflect the spectrum of immature to mature myeloid cells. This heterogeneity suggests that 
there may be no unique marker or combination of phenotypic markers that precisely defines MDSC, 
and that suppressive activity is the ultimate defining characteristic. It is also likely that as this 
population of cells is further studied additional subpopulations and markers will be identified.  
MDSC accumulation and activation are driven by multiple factors, many of which are identified 
with chronic inflammation. Early studies demonstrated that the inflammation-associated molecules 
VEGF and GM-CSF were associated with the accumulation of MDSC [141], suggesting that inflammation 
might facilitate immune suppression [142]. However, it was not until the proinflammatory cytokines 
IL-1β [143] and IL-6 [144] and the bioactive lipid PGE2 [139] were shown to induce MDSC that the 
significance of the association with inflammation was appreciated. These later studies suggested that 
another mechanism by which inflammation promotes tumor progression is through the induction of 
MDSC that block immune surveillance and antitumor immunity, thereby removing barriers that could 
eliminate premalignant and malignant cells. MDSC are induced and/or activated by multiple 
proinflammatory mediators. MDSC accumulate in the blood, bone marrow, lymph nodes, and at tumor 
sites in response to proinflammatory molecules produced by tumor cells or by host cells in the tumor 
microenvironment. These factors include PGE2, IL-1β, IL-6, VEGF, S100A8/A9 proteins, and the 
complement component C5a. 
The heterogeneity of MDSC also complicates finding a single strategy for eliminating the cells. 
Pathologically distinct tumors produce different arrays and quantities of proinflammatory factors that 
induce MDSC. As a result, there is phenotypic heterogeneity between MDSC induced by histologically 
distinct tumors. There is also phenotypic heterogeneity within the MDSC population induced within a 
single individual. This heterogeneity may require identifying and then specifically targeting the 
relevant proinflammatory mediator(s) for individual patients or for the specific type of tumor.  
3.1.5. From Tissue Microenvironment to Tumor Microenvironment 
A widely held view posits, almost axiomatically, that clonal amplification of altered cells fuels 
carcinogenic process by increasing the likelihood that further genetic changes will occur in those 
dividing cells, towards the acquisition of a fully malignant phenotype [145]. Thus, according to this 
view, tumor promotion consists essentially, if not exclusively, in the clonal amplification of altered 
cells, which is per se sufficient to increase the risk for additional genetic hits, thereby fostering cancer 
development. While such interpretation might be theoretically appealing, it is pertinent to point out 
that early focal lesions resulting from tumor promotion (i.e., polyps, papillomas, nodules) are generally 
not associated with the emergence of cellular sub-clones, as the hypothesis above would predict.   
It is also worth reiterating that promotion entails a mainly quantitative phenomenon of selective 
amplification and appears to be driven in many cases by physiological mechanisms involved in normal 
tissue turnover and/or reaction to injury [146]. In this context, the term focal lesion refers to a discrete 
collection of cells displaying a growth pattern and/or histological appearance, which are sufficiently 
distinct from that of the surrounding tissue resulting from the selective expansion of initiated/altered 
cells. According to this view, the focal nature of early lesions represents the critical end point of tumor Int. J. Mol. Sci. 2012, 13 1973 
 
 
promotion in that it forms the basis for the establishment of a new biological niche, with a fundamentally 
altered tissue architecture, which is generally referred to as the tumor microenvironment [82,147]. The 
emergence of the tumor microenvironment from the clonal growth of altered cells represents indeed 
the quantum change brought about by the tumor promotion phase in the natural history of cancer 
development. While the crucial role of the tumor microenvironment in controlling tumor progression 
and metastasis is now widely accepted, the formation of a specialized environment supporting CSC/CIC 
survival and growth (the CSC niche), its anatomical organization and the cellular and molecular 
mediators of these effects, are still under investigation [148]. The recent identification of human normal 
brain cells with self-renewal potential (reported as neural stem cells), that populate the subventricular 
zone, have contributed to the characterization of their niche and to the subsequent identification and 
characterization of brain tumor CSC/CIC and their niche. Brain tumor CSC/CIC are localized in a 
vascular niche that is supposed to provide factors promoting their self-renewal [149,150]. Perturbation 
of this niche, results in a compromised ability CSC/CIC to promote tumor growth within the   
brain [151,152]. These observations demonstrate the relevance of the vascular niche to tumor 
pathophysiology, and suggest the possibility to target the niche itself, and associated molecular events, 
to impinge on CSCs for therapeutic purposes [153,154].  
Many signaling cascades controlling cell growth and proliferation are deregulated in cancers, 
resulting in excessive activation of downstream pathways, by signaling pathways that are not 
functional under nonpathologic conditions, and by alterations in gene expression patterns [4]. These 
situations may involve newly formed interactions between microenvironmental factors and tumor cells 
and between different microenvironmental factors [58,155–158]. These interactions constitute a fertile 
ground for the establishment of circular chains of tumor progression, enhancing events described as 
self-perpetuating cycles. Chemokine-driven self-perpetuating cycles operate in the progression of 
breast carcinomas in mice and humans. Monocyte chemoattractants CCL5 and CCL2 secreted by 
breast tumor cells may induce monocyte infiltration to the microenvironment of breast tumors. The 
resulting tumor-associated macrophages may secrete TNFα, which induces or up-regulates the 
secretion of several promalignancy factors from the tumor cells such as matrix metalloproteinases. 
TNFα also further up-regulates the secretion of CCL5 and CCL2, which drive the merry-go-round for 
another cycle [159]. It is not unlikely that similar cycles operate also in other types of cancer. A recent 
study indicated that a vicious cycle involving the CXCR3-CXCL10 axis and IFNγ operates in 
colorectal carcinoma progression [160]. CXCL10 secreted from CXCR3-expressing colorectal carcinoma 
cells promotes, by an autocrine mechanism, some progression-promoting functions in these tumor cells. 
CXCL10, at the same time, attracts CXCR3-expressing Th1 cells to the tumor site. The infiltrating Th1 
cells secrete IFNγ, which, in addition to its immune functions, promotes the release of CXCL10 from 
IFNγ receptor-expressing colorectal carcinoma cells while up-regulating CXCR3 expression. This 
further promotes the capacity of the colorectal carcinoma cells to respond to CXCL10-mediated 
promalignancy functions. Self-perpetuating cycles involve multiple participants, each of which may 
serve as target for specific adjuvant treatment of metastasis. However, cancer cells are endowed with 
the capacity to bypass regulatory roadblocks or pathways by variety of mechanisms [161,162]. Every 
self-perpetuating cycle described above (and most others) involves numerous cellular interactions. 
Because the blocking of each interaction may be subject to a bypass strategy, we need to use multiple 
therapy modalities targeting most, if not all, components of such self-perpetuating cycles. A series of Int. J. Mol. Sci. 2012, 13 1974 
 
 
biochemical and metabolic changes are typically associated with the tumor microenvironment, being 
attributable, at least in part, to the altered blood and nutrient supply [83]. These changes can both 
induce and select for cell variants within the original focal cell population, setting the stage for the 
emergence and evolution of cell clones which represent the biological hallmarks of tumor progression 
[83,147,163–165]. Consistent with this interpretation, the analysis of multistage models of 
carcinogenesis has clearly documented that the long phase of tumor progression, leading from discrete 
focal lesions to the overt neoplastic phenotype, is a self-perpetuating process and does not depend on 
external manipulation, as it is the case for tumor promotion [146]. Thus, the unique microenvironment 
inside focal lesions, with its associated biochemical and metabolic alterations [83,147,165], appears to 
be sufficient to drive tumor progression. 
3.2. Heterogeneity, Microenvironment and Metastasis 
An understanding of cancer heterogeneity is incomplete without an analysis of metastatic tumors 
and disseminated tumor cells. Cancer is a systemic disease: malignant tumors shed large numbers of 
cells into the blood and lymph vessels, some of them developing in distant sites into metastases. 
Moreover, distant metastasis is responsible for the majority of cancer-related deaths, and, therefore, 
understanding the underlying biological mechanisms of it is of primary importance. The 
invasion/metastasis capability is closely related with cell motility and requires the cytoskeleton as a 
key component, which is also essential during mitoses. As malignancy criteria are mainly related with 
the phenotype of actively proliferating cells, it not surprising that metastatic deposits genetically match 
well differentiated areas of primary neoplasms, and that invasive areas (periphery of solid organ 
neoplasms and deep compartment of luminal organ tumors) show lower cellular turnover and higher 
incidence of genetic abnormalities [8,9,22,23,32]. These factors need attention when planning the 
evaluation of intratumoral heterogeneity and would include: detailed specification of sampling 
(intratumoral location, number of samples), combined evaluation of kinetic and genetic features to 
assess selective process, analysis of pathways at several steps to avoid confounding factors (redundancy 
and pleiotropism) [4,19,166]. These biological foundations will enable a better therapeutic design, 
using the heterogeneity to improve patient’s management.  
There are two main models to explain the intratumoral heterogeneity: random process that would 
result in a patternless distribution or selective process that may be topographically linked and result in 
identifiable compartments including intraepithelial components. The malignancy-associated genetic 
instability can result in independent evolution in different tumor areas, regardless of the location 
(intraepithelial or invasive). Some so-called precancerous lesions show the genetic and kinetic features 
of established malignancies (clonal proliferation with accumulation of cooperative genetic abnormalities, 
and advantageous proliferation/apoptosis dysbalance) [19,25,31,167,168], questioning the 
appropriateness of the name. High-grade lesions are the most reliably diagnosed intraepithelial 
malignancies and progress through multiple morphological and molecular steps, which can and most 
likely include the acquisition of invasion/metastasis capability. As the order of these changes are not 
pre-established, they can be present well before the morphological evidence of malignancy [169], 
which reflect intratumoral heterogeneity and explain the presence of metastasis in cytologically   Int. J. Mol. Sci. 2012, 13 1975 
 
 
low-grade lesions (multiple parallel pathways) that not necessarily progress through high-grade stage 
(linear pathways).  
The connection between early neoplasm stages and metastasis is tumor heterogeneity and 
progression. Progression refers to the acquired capability of cell growth in surrounding or distant 
tissues, reflecting the acquisition of invasive capacities for intraepithelial lesions and metastatic 
capacities for invasive neoplasms. This capability reflects the interaction between tumor cells and the 
microenvironment. It would not be surprising to find similar control for the tumor cell capabilities in 
both steps (stromal invasion and metastasis) [4]. This progression would be related to the accumulation 
of genetic abnormalities and selective segregation of tumor cells with invasive capabilities, which are 
frequently topographically distributed [9,22,23,170]. Clinicopathological studies have demonstrated 
lymph node metastases associated with histologically intraepithelial malignancies (i.e., breast,   
skin) [171,172]. Several intraepithelial foci showed more alterations than matched invasive foci, 
suggesting a more extensive genetic evolution for the former and supporting multifocality and 
independent clonal evolution of these coexistent carcinomas. The accumulation of genetic abnormalities 
in intraepithelial carcinomas is consistent with an advanced molecular stage and progression, along 
with topographic genetic heterogeneity [23,25,30,31,34,167]. Cancer cells are able to survive and 
proliferate only at specific secondary sites where there is an ideal environment that releases molecular 
mediators suitable for that type of cancer cells, still represents a main conceptual model of metastasis 
in modern cancer research [3,173–175]. Metastasis formation itself is a multi-step process that requires 
tumor cells to escape from the primary site, intravasate into the hematic or lymphatic circulation, 
migrate and extravasate into secondary organs [173,176]. Recent work has shed new light on the 
genetic, molecular and cellular basis of metastasis [177–179]. CSC/CIC might represent the unique 
sub-population of cells with the potential to successfully form metastasis in a distant organ [180,181]. 
Metastasis formation, however, is a rather inefficient process, mostly due to the need for a cancer cell 
to find a proper microenvironment for initiating tumor growth in a secondary organ. It has been 
proposed that in order to form metastases, primary tumors might produce factors that induce the 
formation of a suitable and appropriate environment in the organ where metastasis will be seeded. This 
has lead to the concept of the premetastatic niche, whereby a special, permissive microenvironment in 
secondary target organs is induced over distance by the primary tumor [182,183]. In this sense, there is 
a striking parallel between CSC/CIC maintenance and expansion in the primary tumor and formation 
of metastases in a distant organ. Both events require a particular niche or microenvironment and might 
share many cues promoting self-renewal ability, migration and invasion, resistance to apoptosis, and 
increased resistance to cytotoxic drugs. The first in vivo experimental evidence that metastatic seeding 
requires the formation of a niche was the discovery that VEGFR-1
+ BMDC colonize target organs to 
form tumor-specific premetastatic sites, before the arrival of the metastatic tumor cells themselves [184]. In 
these sites BMDC express several hematopoietic markers, such as CD34, CD116, c-kit, Sca-1, as well 
as integrins (e.g., α4β1), chemokines and chemokine receptors (e.g., CXCL12/CXCR4), promoting 
either their homing to the target tissue or recruitment and attachment of tumor metastatic cells, or both. 
What is known about the clonal relationship between tumor cells in primary tumors and metastatic 
sites? According to a traditional model of tumor development, tissue constraints constitute a major 
evolutionary bottle-neck in cancer evolution; thus, the acquisition of metastatic ability is considered to 
be the final step in tumor development, contingent on the acquisition of all of the other hallmarks of Int. J. Mol. Sci. 2012, 13 1976 
 
 
cancer [4–6]. This model implies that metastatic tumors should be genetically similar to the bulk of 
primary tumor cells. 
Many studies that compared the genetic composition of primary tumors and secondary metastatic 
sites have found very close clonal relationships between the two in the majority of cases [185–187]. 
Similarly, analysis of gene expression profiles revealed very similar patterns between primary tumors 
and metastatic sites, a scenario highly unlikely for genetically divergent clones [188–190]. Another 
prediction from the linear model of tumor progression is that different metastases should display close 
clonal relationships among each other. Indeed, this prediction is supported by a recent study that 
compared the genetic composition of anatomically distinct metastatic lesions in 29 prostate cancer 
patients using SNP arrays and CGH [191]. In all cases, different metastatic lesions within the same 
patients demonstrated close clonal relationships, signifying monoclonal origin [191]. This demonstration 
of monoclonality of metastatic cancers is especially interesting given that primary prostate cancers are 
frequently multi-focal [192], and show substantial intra-tumor genetic heterogeneity [192,193].  
While the evidence of the close genetic relationship between primary and metastatic tumors is 
compelling, some cases display dramatic divergence, challenging the model where acquisition of 
metastasis is considered to be the last step of tumor progression. Radically different patterns of allelic 
losses, indicative of a high degree of genetic divergence, have been reported between primary tumors 
and lymph node metastases in prostate cancers [186], and between primary tumors and asynchronous 
metastases in breast cancers [187]. Highly divergent clonal evolution was also evident in a subset of 
cases in CGH studies of primary tumors versus lymph node metastases in breast cancers and of 
primary tumors versus metastatic tumors in renal cell carcinomas [185]. A recent report, comparing 
sequences of primary tumors and metastases in lobular breast cancers, revealed multiple mutations 
present only in metastases and several other mutations with increased frequency in metastatic   
sites [194]. Some of these genetic changes result in higher incidence of apoptosis of tumor cells of 
dormant metastases (more than three fold higher) [195]. These data show that metastases remain 
dormant when tumor cell proliferation is balanced by an equivalent rate of cell death and suggest that 
angiogenesis inhibitors control metastatic growth by indirectly increasing apoptosis in tumor cells. 
Important clues about the clonal evolution of tumors and the relationship between primary tumors 
and metastatic sites can be gained by the analysis of disseminated tumor cells. Because peripheral 
blood, bone marrow, and lymph nodes normally do not contain cells of epithelial origin, cells that have 
disseminated from primary tumors can be detected by the use of epithelial-specific markers, 
cytokeratins and epithelial cell adhesion molecule (EpCAM) [196–200]. Unexpected findings were 
reported by Klein and co-authors, who employed a PCR-based whole-genome amplification technique 
for the analysis of single disseminated tumor cells [201]. The authors demonstrated that disseminated 
tumor cells could be detected both in the bone marrow of patients and in mouse models of cancer at 
very early, pre-invasive stages of breast cancer development [169]. More support for the early 
dissemination of cancer cells came from CGH analysis of disseminated tumor cells from patients 
without overt metastases. These cells contained surprisingly few chromosomal aberrations [202], while 
higher-resolution LOH analysis did confirm the neoplastic origin of these cells and pointed to early 
events in tumor progression [203]. Interesting results were obtained for esophageal cancers, one of the 
most aggressive human carcinomas, where removal of primary tumors does not improve the chances of 
patient survival [204], suggesting the importance of relatively early metastatic spread. Lymph node Int. J. Mol. Sci. 2012, 13 1977 
 
 
and bone marrow metastases showed substantial divergence from primary tumors and among each 
other, suggesting parallel evolution shaped by microenvironment-specific selection forces. Interestingly, 
HER2 amplification in disseminated tumor cells was found to signify poor prognosis, whereas HER2 
amplification in primary tumors had no prognostic value, further underlying the significance of 
divergent evolution between primary tumors and metastatic sites [205]. It should be noted, however, 
that since this analysis, based on the amplification of single-cell genomes, is associated with many 
technical caveats, critical interpretation of the data is highly warranted. 
The obvious caveat of the studies of disseminated tumor cells is that the potential of any given 
disseminated single tumor cell to initiate a metastatic tumor is unknown. The mere fact that tumor cells 
survive at distant sites tells little about their ability to initiate a secondary tumor. Indeed, even normal 
epithelial cells were capable of extended survival in heterotopic sites in an animal model [206], and 
fetal cells are known to survive decades in women following pregnancy [207]. Also, most carcinomas 
display pronounced chromosomal instability, and, therefore, many disseminated cells might be a 
manifestation of “cell-to-cell heterogeneity”, i.e., they are products of genomic instability without any 
substantial chance of clonal expansion. Testing the relevance of these disseminated cells to secondary 
metastasis formation is not trivial. The most compelling evidence comes from a mouse model of breast 
cancer where the growth of lung metastases paralleled that of the primary site from early points of 
tumor progression, and excision of mammary glands when primary tumors were still at the in situ 
stages did not prevent or delay the development of metastases [169]. Tumor cells that disseminated 
from early-stage tumors into the bone marrow were capable of lethal proliferation upon transplantation 
into lethally irradiated mouse recipients [169]. While these findings are compelling, their relevance to 
human cancer is not clear, especially considering that the genetic heterogeneity of disseminated cancer 
cells in mouse tumors appears to be less pronounced than that in human tumors. 
Another group demonstrated that bone marrow aspirates from carcinoma patients contain 
disseminated tumor cells that are capable of proliferation in cell culture and that the extent of this 
proliferation is inversely correlated with patient survival [208]. CGH analysis of disseminated tumor 
cells from breast cancer patients confirmed their high divergence from primary tumors [209]. This 
study demonstrated substantially higher numbers of genomic abnormalities in disseminated tumor cells 
compared to the studies of Klein et al., despite similar staging of the tumors analyzed, suggesting that 
the ability of disseminated cells to form metastases is contingent on the acquisition of a large number 
of genetic alterations. Additional evidence for parallel clonal evolution comes from the detection of 
metastatic tumors with unknown primary origin, which constitute a significant fraction of clinical 
cases [210]. In addition, analysis of the growth kinetics of primary and metastatic tumors is 
inconsistent with metastatic spread being a late event [211].  
Clearly, more studies are required to clarify the clonal relationship between primary and metastatic 
tumor cell populations, as this relationship could not only illuminate the evolutionary history of cancer 
development, but also create a more solid ground for therapeutic decision making. Currently, the 
majority of therapeutic decisions are being made based on the analysis of primary tumor specimens. 
Yet, this approach could only be justified in cases where the genetic compositions of primary and 
metastatic tumors are similar, especially when making decisions about emerging therapeutic approaches 
that target specific genetic changes. In addition, elucidating the issue of early versus late origin of 
metastasis-initiating cells is important for determining the usefulness of therapeutic approaches that Int. J. Mol. Sci. 2012, 13 1978 
 
 
target tumor cell invasion. The question of clonal heterogeneity within metastases remains unexplored, 
and, notably, clonal heterogeneity within primary tumors has limited direct therapeutic relevance, as in 
most cases primary tumors can be successfully removed by surgery, but this is most often not the case 
for metastatic outgrowths. Therefore, elimination of metastatic clones has to rely on adjuvant therapies, 
and it is likely that the success of these therapies will depend on the extent of the heterogeneity of 
these tumor cell populations. 
4. Mechanisms Involved in Intra-Tumor Heterogeneity and Progression 
Any type of cancer progresses through a relatively narrow evolutionary trajectory [212], “jackpot” 
mutations, which endow mutant clones with the ability to achieve selective sweeps, are likely to be 
very rare [4,16,18,19]. Most of the spontaneous mutations that occur are neutral or deleterious, and, 
while grossly disadvantageous mutations will be discarded, neutral or near-neutral mutations can 
undergo expansions due to genetic drift and can sometimes reach fixation in small tumors [60]. Tumor 
initiation and progression are dependent on rare, stochastic mutational events, and the chances of any 
given individual getting diagnosed with a particular cancer within a limited timeframe are relatively 
low, suggesting that cancers have to be clonal in origin, i.e., they are likely to arise from a common 
progenitor. This consideration, supported by substantial experimental evidence, has led to a wide 
acceptance of the clonal origin of cancers [213,214], although there might be some rare exceptions in 
cases of hereditary cancers [215]. Rare mutations confer competitive advantage through cellular 
selection, resulting in clonal dominance. Even though most cancers start from a single mutated cell, 
mechanisms that constrain clonal evolution in populations of normal progenitor cells are no longer 
fully functional in tumors, allowing for an ongoing evolutionary process in populations of tumor   
cells [216]. Multiple rounds of proliferation, often counter-balanced by cell death, are required to 
produce macroscopic tumors, and genomic instability, observed in most cancers, is expected to 
constantly produce new mutations, which serve as raw material on which tumor evolution can work.  
Moreover, spatial constraints that exist within a tumor can slow down the achievement of clonal 
dominance by substantially inhibiting competition among different tumor cell clones [9,10,22,23,34,166,217]. 
The importance of spatial constraints for the emergence and maintenance of clonal heterogeneity is 
supported by experimental observations in colon cancer as well as in silico modeling [218]. In addition 
to providing barriers to competition, spatial intra-tumor heterogeneity can support the co-existence of 
genetically distinct clones by affecting selective pressures. Most tumors represent at least partially 
structured habitats where individual cells within a tumor are experiencing differences in interactions 
with ECM, physical contact with other cells (both tumor and non-tumor), and gradients of oxygen, 
nutritional and growth factors, and metabolites. Therefore, tumor cells within different parts of tumors 
could be expected to experience different selective pressures, leading to the selection of different sets 
of mutations. 
Mathematical modeling suggests that, even in the absence of substantial spatial heterogeneity, 
evolving pre-malignant tumors are likely to be characterized by quasi-steady states with the co-existence 
of multiple populations with different “strategies”. However, a clone that evolves toward invasive 
cancer will be capable of invading and destroying pre-malignant populations [219,220].  Int. J. Mol. Sci. 2012, 13 1979 
 
 
4.1. Hypoxia: Intratumor Variability and Influence on Metastasis 
Hypoxia or oxygen deficiency is a salient feature of locally advanced solid tumors resulting from an 
imbalance between oxygen (O2) supply and consumption. Major causative factors of tumor hypoxia 
are abnormal structure and function of the microvessels supplying the tumor, increased diffusion 
distances between the nutritive blood vessels and the tumor cells, and reduced O2 transport capacity of 
the blood due to the presence of disease- or treatment-related anemia. Heterogeneities in tumor blood 
flow are associated with cyclic changes in pO2 or cyclic hypoxia. A major difference from O2 
diffusion-limited or chronic hypoxia is that the tumor vasculature itself may be directly influenced by 
the fluctuating hypoxic environment, and the reoxygenation phases complicate the usual hypoxia-induced 
phenotypic pattern. Hypoxia induces a number of genes responsible for increased invasion, 
aggressiveness, and metastasis of tumors, including genes related with ECM interactions, migration, 
and proliferation [221]. Within a given tumor, there was an inverse correlation between regions of 
proliferation (Ki-67) and regions of hypoxia. The relationships between hypoxia and other biologic 
endpoints are complex, but, within a given tumor’s spatial relationships, they are in accord with known 
physiologic principles. Necrosis, proliferation, and blood vessel distribution cannot predict the level  
or presence of hypoxia in an individual tumor [222]. The exposure of endothelial cells to cycles of 
hypoxia/reoxygenation led to accumulation of HIF-1alpha during the hypoxic periods and the 
phosphorylation of protein kinase B (Akt), extracellular regulated kinase (ERK) and endothelial nitric 
oxide synthase (eNOS) during the reoxygenation phases. Cyclic hypoxia, as reported in many tumor 
types, as a unique biological challenge for endothelial cells that promotes their survival in a   
HIF-1alpha-dependent manner through phenotypic alterations occurring during the reoxygenation 
periods [223].  
Histopathological examination of solid tumors frequently reveals pronounced tumor cell 
heterogeneity, often demonstrating substantial diversity within a given tumor. The molecular 
mechanisms underlying the phenotypic heterogeneity are very complex with genetic, epigenetic and 
environmental components, such as shortage in oxygen. Hypoxic tumors appear to be poorly 
differentiated. Increasing evidence suggests that hypoxia has the potential to inhibit tumor cell 
differentiation, thus playing a direct role in the maintenance of CSCs, also blocks differentiation of 
mesenchymal stem/progenitor cells, a potential source of tumor-associated stromal cells. It is   
therefore likely that hypoxia may have a profound impact on the evolution of the tumor stromal 
microenvironment, facilitating tumor progression. Hypoxia may help create a microenvironment 
enriched in poorly differentiated tumor cells and undifferentiated stromal cells. Such an undifferentiated 
hypoxic microenvironment may provide essential cellular interactions and environmental signals for 
the preferential maintenance of CSCs [224]. Hypoxia greatly influences cellular phenotypes by altering 
the expression of specific genes, makes the tumors more aggressive (Figure 1), and is an important 
contributor to intra- and inter-tumor cell diversity as revealed by the pronounced but non-uniform 
expression of hypoxia-driven genes in solid tumors [225]. Hypoxic tumor cells lose their differentiated 
gene expression patterns and develop stem cell-like, immature or dedifferentiated phenotypes. 
Hypoxia-induced dedifferentiation will not only contribute to tumor heterogeneity but could also be 
one mechanism behind increased aggressiveness of hypoxic tumors. A state of hypoxia is a universal 
characteristic of the microenvironment of solid tumors. Growing evidence indicates that hypoxia plays Int. J. Mol. Sci. 2012, 13 1980 
 
 
a critical and fundamental role in metastasis formation [226]. Hypoxia drives tumor progression by 
influencing both the tumor cells as well as the tumor microenvironment (Figure 4). It increases 
genomic instability and heterogeneity in tumor cells and selects resistant tumor variants. It also alters 
the expression of several genes, among them hypoxia-inducible factor 1, a transcription factor that 
regulates a large variety of key genes controlling cell survival, migration, and angiogenesis to name 
just a few [227,228]. Hypoxia and hypoxia-inducible factor 1 mediate progression-promoting or 
progression-restraining effects on tumor cells and on the microenvironment. These activities involve, 
on the one hand, regulation of genes that drive tumor progression [227,228], and, on the other hand, 
the induction of genes that may cause the opposite effect. (e.g., cell death). By surviving and propagating 
under hypoxia, resistant tumor cells further aggravate the state of tumor hypoxia. This, in turn, increases 
genomic instability and further stabilizes and activates hypoxia-inducible factor 1. This vicious cycle 
drives alterations of gene expression patterns in tumor cells and thereby enhances tumor progression.  
Figure 4. Differential gene regulation in neoplasms. This process is related with 
extracellular suppressive mechanisms and RNA delivering through exosomes, hypoxic 
microenvironment, and epigenetics (methylation and histone modifications). 
 
Hypoxia promotes each step of the metastatic cascade, including the promotion of angiogenesis and 
lymphangiogenesis, the induction of changes in vascular integrity and permeability (that facilitate 
tumor cell intravasation and extravasation), as well as cell proliferation [4]. Most of these mechanisms 
are regulated by HIF-induced VEGF action, which become connected with the coexpression through Int. J. Mol. Sci. 2012, 13 1981 
 
 
pVHL and might enable tumor progression and metastatic dissemination by autocrine receptor 
stimulation [229]. Hypoxia greatly influences cellular phenotypes by altering the expression of specific 
genes, makes the tumors more aggressive, and is an important contributor to intra- and inter-tumor cell 
diversity as revealed by the pronounced but non-uniform expression of hypoxia-driven genes in solid 
tumors [225]. Intratumoral hypoxia is an independent indicator of poor patient outcome and increasing 
evidence supports a role for hypoxia in the development of metastatic disease [225]. Studies suggest 
that the acquisition of the metastatic phenotype is not simply the result of dysregulated signal 
transduction pathways, but instead is achieved through a stepwise selection process driven by   
hypoxia [230–232]. Through upregulation of urokinase-type plasminogen activator receptor (uPAR) 
expression [233], hypoxia enhances proteolytic activity at the invasive front and alters the interactions 
between integrins and components of the ECM, thereby enabling cellular invasion through the 
basement membrane and the underlying stroma [229,234,235]. Cell motility is increased through 
hypoxia-induced hepatocyte growth factor (HGF)-MET receptor signaling, resulting in cell migration 
towards the blood or lymphatic microcirculation. Hypoxia-induced vascular endothelial growth factor 
(VEGF) activity also plays a critical role in the dynamic tumor-stromal interactions required for   
the subsequent stages of metastasis [236]. HIF1-induced VEGF promotes angiogenesis and 
lymphangiogenesis, providing the necessary routes for dissemination, induces changes in vascular 
integrity and permeability that promote both intravasation and extravasation, and is essential for cell 
proliferation in metastatic lesions. 
The important steps that enable metastasis are reversible, and therefore cannot be explained solely 
by irreversible genetic alterations, indicating the existence of a dynamic component to human tumor 
progression, in particular a regulatory role for the tumor microenvironment [178]. Hypoxic tumor cells 
lose their differentiated gene expression patterns and develop stem cell-like, immature or 
dedifferentiated phenotypes [102]. Hypoxia-induced dedifferentiation will not only contribute to tumor 
heterogeneity but could also be one mechanism behind increased aggressiveness of hypoxic tumors. 
The loss of epithelial characteristics (i.e., lack of intercellular adhesion molecules) results in 
breakdown of epithelial-cell homeostasis, correlates with the acquisition of a migratory and stem   
cell phenotype that leads to progression, and it is regulated by CXCR4-CXCL12 [237]. The epithelial 
to mesenchymal transition is considered to be a crucial event in malignancy [238]. Tumors are 
morphological and functionally heterogeneous and segregate tumor cell with different capabilities: 
individual tumor shows distinct sub-areas of proliferation and cell-cycle arrest, differentiation, cell 
adhesion and dissemination, some of them determined by topography [4,8–10,16,22,23,32,81,217,239]. 
Supporting this concept, topographic analysis of HIF1 and stem cell markers in follicular thyroid 
neoplasms has shown direct correlation. Hypoxia facilitates disruption of tissue integrity through 
repression of E-cadherin expression, with concomitant gain of N-cadherin expression, which allows 
cells to escape anoikis [4]. Neoplastic transformation evolves over a period of time involving the 
phenotypic progression of tumor cells along with the interaction of the initiated cell with its 
microenvironment. Tumor cell dissemination is the prerequisite of metastases and is correlated with 
loss of epithelial differentiation and the acquisition of a migratory phenotype through a stepwise, 
irreversible accumulation of genetic alterations [177,180,238]. The molecular mechanisms led by 
hypoxia explain the general phenotype associated with progression (metastatic capability): spindle-shaped 
cellularity, necrosis and stem cell phenotype. CXCR4-CXCL12 and hypoxia play a central role on the Int. J. Mol. Sci. 2012, 13 1982 
 
 
metastatic process (stromal interaction and digestion, angiogenesis), maintaining stem cell features in 
the tumor cells. Metastasis is considered the final step in malignancy that results from selected aspects 
of the complex tumor-progression process. However, this capability can be acquired early during the 
natural history of neoplasms and has a complex molecular regulation, for which the interaction tumor 
cell-stroma is essential. The chemokine axis CXCR4-CXCL12 has demonstrated a central role in this 
mechanism [240,241], involving both endothelial cells interactions and expression of 
metalloproteinases [229,233,242]. The central role of hypoxia in tumor progression-metastasis would 
also explain the general phenotype associated with progression (metastatic capability): spindle-shaped 
cellularity, necrosis and stem cell phenotype. CXCR4-CXCL12 and hypoxia play a central role on the 
metastatic process (stromal interaction and digestion, angiogenesis), maintaining stem cell features in 
the tumor cells. Among the chemokines involved in tumor metastasis, the CXCL12 (also known as 
SDF-1 or stromal-derived factor)/CXCR4 axis plays a critical role in stem cell migration. Activation of 
CXCR4 induces motility, chemotactic response, adhesion, secretion of MMPs and release of angiogenic 
factors, such as VEGF-A. Interestingly this premetastatic niche, like the normal niche, is characterized 
by the presence of specific ECM proteins, such as fibronectin, a ligand for α4β1 expressed on VEGFR-1
+ 
cells. Thus, it appears that in order to survive at distant sites, disseminating tumor cells need to recreate 
a supportive microenvironment similar to the one formed in the primary tumor. One efficient way to 
do it is by directing BMDC or immune/inflammatory cells to these distant sites of future metastasis [243]. 
The chemoattractant proteins S100A8 and S100A9 were the first factors shown to instruct the 
formation of the premetastatic niche [183,244]. Additional studies are needed to further elucidate the 
biological mechanisms involved in the formation of this premetastatic niche, in particular regarding the 
identification of the molecular mechanism responsible for the development of clinically relevant 
metastases from the initial seeds.  
4.2. Regulation of Gene Expression: Exosomes and Epigenetics 
The phenotypic heterogeneity in neoplasms is mainly related with differential gene expression. 
Gene expression analysis is becoming a useful tool for a better definition of neoplasms at diagnostic, 
prognostic and predictive levels. The identification of predictive markers of these features will help 
classifying neoplasms and stratifying patients for a better management. However, the nature and 
biological meaning of these gene expression markers is not always clear: origin of the tested RNA, 
mechanism of RNA transference, utility for subclassification of neoplastic lesions. 
Gene expression analysis is becoming a useful tool for a better definition of neoplasms at diagnostic, 
prognostic and predictive levels [245–249]. Tumor hypoxia induces changes in the proteome and 
genome of neoplastic cells that enable the cells to overcome nutritive deprivation or to escape their 
hostile environment. The selection and clonal expansion of these favorably altered cells further 
aggravate tumor hypoxia and support a self-perpetuating circle of increasing hypoxia and malignant 
progression while concurrently promoting the development of more treatment-resistant disease [250]. 
The Met tyrosine kinase, a high affinity receptor for hepatocyte growth factor (HGF), plays a crucial 
role in controlling invasive growth and is often overexpressed in cancer. Hypoxia activates MET 
protooncogene transcription, amplifies HGF (hepatocyte growth factor) signaling, and synergizes with 
HGF in inducing invasion; the proinvasive effects of hypoxia are mimicked by Met overexpression Int. J. Mol. Sci. 2012, 13 1983 
 
 
(Figures 2 and 4). Hypoxic tumor areas overexpress Met and the inhibition of Met expression prevents 
hypoxia-induced invasive growth. These data show that hypoxia promotes tumor invasion by 
sensitizing cells to HGF stimulation, providing a molecular basis to explain Met overexpression in 
cancer [251]. There is also a link between a specific group of microRNAs and hypoxia, a key feature 
of the neoplastic microenvironment: A significant proportion of the hypoxia-regulated microRNAs 
(HRMs) are also overexpressed in human cancers, suggesting a role in tumorigenesis, affecting 
important processes such as apoptosis, proliferation and angiogenesis. Several HRMs exhibit induction 
in response to HIF activation [252].  
The gene expression signature also reflects the metastatic potential in both cell lines and tumor 
samples [253–257]. Some general conclusions have been drawn in this respect. First, the expression 
profile of low metastatic subline is distinct from that of the high metastatic subline. Metastases of the 
low metastatic subline closely resembled the profile of the low metastatic primary tumor, and did not 
“switch over” to the high metastatic gene expression profile. Thus, heterogeneity exists in this cell 
line/tumor, but may not be apparent as the signature reflects the majority of the tumor cells. The low 
metastatic subline is capable of spawning metastases, albeit at a lower rate, and its gene expression 
profile is therefore of significant interest. Second, the gene expression profile of the sublines as in vitro 
cultures is very distinct from the same sublines as primary tumors. While the primary tumors are a 
mixture of tumor cells, stromal cells, endothelial cells, etc, the contribution of these cells to the 
observed gene expression profiles should be minimal. Thus, the differences are thought to reflect 
changes in the tumor cells in response to the in vivo microenvironment. Third, comparable numbers of 
genes were “turned on” and “turned off” in the more highly metastatic tissues. We think about 
metastasis as the acquisition of traits, but the data remind us to pay equal attention to the loss of 
growth and differentiation-controlling genes. Many of the differentially expressed genes fall into the 
category of “usual suspects” for metastasis. These include the overexpression of osteopontin and ECM 
genes in the more metastatic tissues, and the loss of thrombospondin 1 and members of the Nm23 
family [247]. Eight metastasis-suppressor genes that reduce the metastatic propensity of a cancer cell 
line  in vivo without affecting its tumorigenicity have been identified. These affect important   
signal-transduction pathways, including mitogen-activated protein kinases, RHO, RAC and   
G-protein-coupled and tyrosine-kinase receptors [255]. Other genes are unexpected and, if validated 
functionally, could shed new light on the mechanisms of metastasis. 
Cancer cells communicate with the environment through delivery of surface proteins, release of 
soluble factors (growth factors and cytokines), and sophisticated nanovehicles (exosomes) for 
establishment of invasive tumor growth. A central question in molecular studies is to determine the 
cellular origin of the target mRNA. Two biological aspects are essential for this process: how the 
tumor mRNA gets there and the functionality of this mRNA. This is most relevant in locations where 
the tumor cells are scanty and the expression profile support higher tumor cell load [258]. Most of the 
cases of malignant melanomas do not show enough number of superficial tumor cells to explain the 
positive findings in superficial samples [259]. In this context, the RNA cannot be directly provided by 
the tumor cells but by keratinocytes through a transfer process similar to what happens with melanin. 
Membrane vesicles derived from both tumor and host cells have recently been recognized as new 
candidates with important roles in the promotion of tumor growth and metastasis [260]. The transfer of 
membrane components between donor and acceptor cells has been described “trogocytosis” (from Int. J. Mol. Sci. 2012, 13 1984 
 
 
Greek “trogo”, meaning “gnaw” or “bite”). Two forms of membrane transfer (trogocytosis) have been 
described: via nanotubes or via membrane vesicles [261]. The biogenesis of membrane vesicles 
essentially distinguishes exosomes from shedding microvesicles and apoptotic blebs (Figures 2 and 4). 
Microvesicles (exosomes) containing mRNA and miRNA can be taken up by normal host cells, such 
as keratinocytes or endothelial cells, and translated by recipient cells [262]. Exosomes are specialized 
membranous nano-sized vesicles derived from endocytic compartments that are released by many cell 
types; they are formed by the inward budding of multivesicular bodies (MVBs) and are released from 
the cell into the microenvironment following the fusion of MVBs with the plasma membrane [263]. 
Intercellulars communication occurs in part through constitutive exocytosis, regulated exocytosis, or 
release of intraluminal vesicles, and is modulated by small Rab GTPases, the master regulators of 
vesicle traffic. Rab GTPases are implicated in regulated exocytosis and have showed a unique role for 
Rab27B in invasive tumor growth. Emerging evidence indicates that various exocytic routes are 
implemented by cancer cells to relay crucial information for fostering growth, migration, and matrix 
degradation [264]. Tumor-derived microvesicles therefore serve as a means of delivering genetic 
information and proteins to recipient cells in the tumor environment, and the subset of tumor 
suppressive microvesicles are key elements of tumor-related suppression mechanisms by accumulations 
of adenosine-producing regulatory T-cells in the tumor microenvironment and expression of toll-like 
receptors on the tumor cell surface [265]. It has been suggested that microvesicles shed by certain 
tumor cells hold functional messenger RNA (mRNA) that may promote tumor progression. Purified 
exosomes contain functional microRNAs (miRNAs) and small RNA, but detected little mRNA. 
Exosomes are specialized in carrying small RNA including the class 22–25 nucleotide regulatory 
miRNAs. Both the evidence provided from studies on exosomes and the lack of the expected 
phenotypic changes in keratinocytes from the expression of putative melanoma markers in the study 
support a transfer of predominant short RNA rather than functional mRNA [259,262]. The discovery 
of extracellular miRNAs (including miR-21), existing either freely or in exosomes in the systemic 
circulation, has led to the possibility that such molecules may serve as biomarkers for ongoing patient 
monitoring [266]. There is increasing evidence that miRNAs have potential not only to facilitate the 
determination of diagnosis and prognosis and the prediction of response to treatment, but also to act as 
therapeutic targets and replacement therapies [267,268]. The biological heterogeneity in neoplasm and 
precancerous lesions would potentially make more difficult these assessments [34,269,270]. We only 
have to consider that deep tumor compartments provide more accurate prognostic information in 
melanomas and dermal compartments rather than the junctional compartments better define dysplastic 
melanocytic lesions.  
The biologic heterogeneity of intraepithelial and invasive malignancies is well known at the 
morphologic, kinetic and genetic levels (Figure 1), an issue that has not been addressed in this 
paratumoral gene expression analysis and should warrant future studies. The gene expression markers 
should be evaluated in the appropriate biological context. Gene expression profiles are determined by a 
gene regulatory network comprising regulatory core of genes represented most prominently by 
transcription factors and miRNAs, which influence the expression of other genes, and a periphery of 
effector genes that are regulated but not regulating [271,272]. Most studies do not differentiate 
between these two essential groups, which can be also useful in selecting surrogate markers for a given 
condition [4,271]. There is a general concept to keep in mind for gene expression analyses: the amount Int. J. Mol. Sci. 2012, 13 1985 
 
 
of information is overwhelming and the number of variables included in the studies significantly 
outnumbers the cases. In this scenario, the significant variables can be the result of a statistical 
selection rather than the expression of a biologically significant process for a particular neoplasm. 
Supporting this aspect, significant variables frequently include genes of the general metabolic 
activation associated with the neoplastic transformation [4,5], rather than tissue- or differentiation-specific 
gene variables. 
Epigenetic dysregulation is central to cancer development and progression (Figure 4) [273]. The 
best-known epigenetic marker is DNA methylation. This dysregulation includes hypomethylation 
leading to oncogene activation and chromosomal instability, hypermethylation and tumor suppressor 
gene silencing, and chromatin modification acting directly, and cooperatively with methylation 
changes, to modify gene expression [274]. The initial finding of global hypomethylation of DNA in 
human tumors was soon followed by the identification of hypermethylated tumor-suppressor genes, 
and then, more recently, the discovery of inactivation of microRNA (miRNA) genes by DNA 
methylation. (I) DNA methylation occurs in a complex chromatin network and is influenced by the 
modifications in histone structure that are commonly disrupted in cancer cells [273]. Three mechanisms 
have been proposed to explain the contribution of DNA hypomethylation to the development of a 
cancer cell: generation of chromosomal instability, reactivation of transposable elements, and loss of 
imprinting. Undermethylation of DNA can favor mitotic recombination, leading to deletions and 
translocations [275,276], and it can also promote chromosomal rearrangements. This mechanism was 
seen in experiments in which the depletion of DNA methylation by the disruption of DNMTs caused 
aneuploidy [277]. Hypomethylation of DNA in malignant cells can reactivate intragenomic endoparasitic 
DNA, such as L1 (long interspersed nuclear elements), and Alu (recombinogenic sequence) repeats 
[278]. These undermethylated transposons can be transcribed or translocated to other genomic regions, 
thereby further disrupting the genome. (II) Hypermethylation of the CpG-island promoter can affect 
genes involved in the cell cycle, DNA repair, the metabolism of carcinogens, cell-to-cell interaction, 
apoptosis, and angiogenesis, all of which are involved in the development of cancer [279]. 
Hypermethylation occurs at different stages in the development of cancer and in different cellular 
networks, and it interacts with genetic lesions. Such interactions can be seen when hypermethylation 
inactivates the CpG island of the promoter of the DNA-repair genes hMLH1, BRCA1, MGMT  
(O
6-methylguanine–DNA methyltransferase), and the gene associated with Werner’s syndrome (WRN) 
[280-282]. In each case, silencing of the DNA-repair gene blocks the repair of genetic mistakes, 
thereby opening the way to neoplastic transformation of the cell. (III) Hypermethylation of the CpG 
islands in the promoter regions of tumor-suppressor genes in cancer cells is associated with a particular 
combination of histone markers: deacetylation of histones H3 and H4, loss of H3K4 trimethylation, 
and gain of H3K9 methylation and H3K27 trimethylation [27,283]. The presence of the hypo-acetylated 
and hypermethylated histones H3 and H4 silences certain genes with tumor-suppressor–like properties, 
such as p21
WAF1, despite the absence of hypermethylation of the CpG island. In human tumors 
generally, modifications of histone H4 entail a loss of monoacetylated and trimethylated forms [284]. 
These changes appear early and accumulate during the development of the tumor [284]. (IV) Short,  
22-nucleotide, non-coding RNAs that regulate gene expression by sequence-specific base pairing in 
the 3’ untranslated regions of the target mRNA are called miRNAs. The result is mRNA degradation 
or inhibition of translation [285]. DNA hypermethylation in the miRNA 5’ regulatory region is a Int. J. Mol. Sci. 2012, 13 1986 
 
 
mechanism that can account for the down-regulation of miRNA in tumors [286]. In colon-cancer cells 
with disrupted DNMTs, hypermethylation of the CpG island does not occur in miRNAs [286]. The 
methylation silencing of miR-124a also causes activation of the cyclin D–kinase 6 oncogene (CDK6), 
and it is a common epigenetic lesion in tumors [286].  
5. Clinical Implications 
5.1. Diagnosis: Sampling and Genetic Targets 
The application of the so-called hallmarks of cancer in oncological pathology leads to consideration 
of the molecular test requirements (Molecular Test Score System) for reliable implementation; these 
requirements should cover biological effects, molecular pathway, biological validation, and technical 
validation [4]. Sensible application of molecular markers in tumor pathology always needs solid 
morphological support.  
Additionally, any new test should be validated against the accepted standard (specificity/sensitivity), 
demonstrate improvements of patient’s management, and should provide a biologic meaning for its 
application. These requirements could be considered as implementation phases: The first requirement 
is normally met on the initial design, the second requirement would be expected in any successful 
implementation, while the third is more difficult to prove. Any new definition should be biologically 
meaningful and would incorporate core elements in tumor biology (in particular genetic and kinetic 
correlates). Examples include the PAX8/PPAR fusion gene described in follicular thyroid carcinomas 
and adenomas, or RET/PTC fusion genes reported in papillary thyroid carcinomas and Hashimoto’s 
thyroiditis. Apart from the lack of general interest, the scarcity of definitive publications on clonal 
heterogeneity can be attributed to the substantial technical challenges faced by researchers who want to 
study genetic heterogeneity in human cancers. Several approaches have been used to study genetic 
heterogeneity, which need to address the issue of inadequate sampling and technical caveats arising 
from the frequent necessity to analyze limited amounts of starting material. It is useful to divide the 
approaches to study clonal heterogeneity into focused and genome-wide methods. 
5.1.1. Sampling Issues 
One of the obvious challenges of studying clonal heterogeneity in human malignancies is the issue 
of sampling. One aspect of this problem is the availability of representative biopsies. Core biopsies, 
obtained for diagnostic purposes, sample only small regions of tumors, and, therefore, are not likely to 
be informative about the clonal composition of each tumor as a whole. Thus, adequate analysis of 
intra-tumor clonal heterogeneity often relies on access to post-surgical samples from different regions 
of tumors [9–11,22,23,30,217]. 
Sample size is another important issue [17,18,28]. When a tumor specimen is too large, most 
methods will only provide an average picture, usually reflecting the dominant clone. Thus, potential 
heterogeneity would be missed: while large numbers of cells pooled will quench the “noise”, signal 
from minor subpopulations will be lost. The exception is deep sequencing of whole genomes, which 
allows for the detection of mutant alleles present in a small fraction of tumor cells [194]. On the other 
end of the spectrum, many of the analyses suitable for the characterization of clonal heterogeneity can Int. J. Mol. Sci. 2012, 13 1987 
 
 
be performed with starting material of just single cells [201]. Focusing on single cells, however, brings 
about the problem of dealing with cell-to-cell variability, where some of the distinguishable variants 
have no chances of clonal expansion and thus constitute evolutionary “dead ends”. This problem of 
biological noise can potentially be dealt with by analyzing larger numbers of individual cells, but 
scaling up the analysis will inevitably drive up the cost and labor required, making these studies 
impractical. Moreover, single-cell analysis suffers from increased vulnerability to technical caveats 
related to the necessity to amplify single genomes prior to the analysis (discussed below). 
Therefore, with respect to sample size, there is a need to balance signal-to-noise ratios. Many 
studies achieve this balance by focusing on relatively small regions of tumors, ideally representing 
morphologically distinct units that are isolated by microdissection. The validity of this approach is 
supported by the observation of the clustering of populations that differ in gene expression [287], as 
well as genetic composition [218]. However, sampling small regions of tumors can still miss relatively 
small patches of genetically distinct cells, unless large numbers of samples are taken from the 
individual tumors [17,18,28]. In addition, if genetically distinct clones are intermixed within small 
anatomically distinct units, such heterogeneity will be missed due to pooling of cells. 
Another approach to sampling is based on the analysis of phenotypically distinct subpopulations 
after singling them out by FACS, by immunobead separation or by morphological appearance and 
microdissection. For example, analysis of the genomic composition of CD44
+CD24
− and CD44
−CD24
+ 
breast carcinoma cells has revealed the existence of unexpected clonal divergence between the two 
populations in some tumor samples [288]. Obviously, this approach can be valid only for the cases 
when phenotypic differences can be related to differences in genetic composition, and genetic 
heterogeneity within the populations will be missed. 
5.1.2. Focused Approaches 
In focused approaches, analysis is limited to a particular genetic locus or a set of loci. The 
advantage of focused approaches is that they allow for the analysis of specific genes that have been 
implicated as drivers of tumor progression. Current knowledge of cancer genetics permits focusing on 
genetic lesions specific for types and subtypes of a particular cancer. The obvious disadvantage of 
these methods is that limiting analysis to a few loci will miss other potentially important differences 
and will likely underestimate the extent and patterns of clonal heterogeneity. 
Most of the published reports on intra-tumor clonal heterogeneity have relied on the detection of 
allelic imbalances. Most commonly, this analysis is performed on microdissected tumor samples to 
ensure lack of contamination by normal cells and to provide adequate sample sizes. The DNA is then 
isolated from the captured cells, and PCR is performed using primers against microsatellite markers 
specific to regions that have previously been characterized as being frequently altered in the particular 
type or subtype of cancer under study. Comparison to controls, germline samples from the same 
patients, allows for the detection of alleles that have been lost somatically. Although obtaining data is 
relatively simple, straightforward interpretation is obscured by multiple technical caveats, such as 
frequently poor correlation between chromosomal deletion/amplification and under/overrepresentation 
of relevant microsatellite markers [289]. Therefore, data obtained by analysis of allelic imbalances 
often requires confirmation by independent techniques. Int. J. Mol. Sci. 2012, 13 1988 
 
 
Studies of clonal heterogeneity may rely on the detection of amplification of specific chromosomal 
regions by fluorescent in situ hybridization (FISH) or immuno-FISH (FISH coupled with 
immunofluorescence) analysis [42,288]. In FISH analysis, fluorescently labeled BAC (bacterial 
artificial chromosome) probes against regions amplified in the particular cancer type, as well as control 
probes for centromeric regions, are hybridized to cancer cells or tissue sections. Combination with 
immunofluorescence provides the advantage of focusing on specific subtypes of tumor cells. FISH 
analysis is less vulnerable to artifacts than are other approaches, such as analysis of allelic imbalances; 
thus, it can be the approach of choice for the validation of differences initially detected by other means. 
Disadvantages include its labor-intensiveness, as large numbers of cells need to be analyzed in order to 
generate statistically meaningful data. Also, although potentially suitable for the analysis of 
chromosomal deletions, detection of amplified regions is more practical. 
Clonal heterogeneity can be assessed by sequencing specific genes known to be frequently mutated 
in a particular cancer [218,290]. This analysis usually involves microdissection and PCR amplification 
of the samples. The major advantage of sequencing is that it allows for focusing on specific “driver” 
genes; thus, any heterogeneity will most likely be of functional importance. Intensive studies in the 
field of cancer genetics, and recent sequencing of cancer genomes and allowed the identification of 
cancer-type-specific subsets of genes that “drive” cancer progression [288,291,292]. Therefore, it 
should be feasible to analyze samples for sets of genes causally implicated in a given cancer. Also, 
instead of the detection of specific nucleotide changes, bisulfite sequencing of specific alleles can be 
used to detect heritable methylation changes either in promoters of “driver” genes or in a larger set of 
“passenger” sites, which can be used as markers to trace clonal expansion patterns [293].  
Lymphoid malignancies sometimes present another unique opportunity for focused clonality 
analysis. Early steps of development of B and T cells involve step-wise rearrangements of 
immunoglobulin (Ig) and T-cell receptor (TCR) genes, respectively. Germline loci for Ig and TCR 
genes contain multiple alternative gene segments, encoding for gene domains, that are randomly 
chosen for rearrangements to generate thousands to millions (depending on the gene) potential mature 
rearranged products distinguishable by PCR. While, in most cases, a given leukemia or lymphoma 
arises from a cell with completed rearrangement, and, thus, all of the cells in the malignancy start with 
an identical rearrangement, the immunogene loci often undergo further rearrangements through 
recombination or somatic hypermutation, providing a pattern that can be used to analyze evolutionary 
relationships among distinct clones [294,295]. Combining PCR and deep sequencing appears to be an 
especially promising way to analyze this, as it allows for the detection of rare subclones without   
a priori knowledge of the products of rearrangements [155,296]. One potential drawback is that the 
subclonal changes might have no effect on fitness, i.e., they are evolutionarily neutral. However, the 
approach is still useful given that it allows for establishing evolutionary relationships between primary 
disease and relapses [297,298], and permits tracing the evolutionary history of leukemias.  
5.1.3. Genome-Wide Approaches 
Instead of focusing on particular loci, whole genomes can also be analyzed in clonal heterogeneity 
studies. An obvious advantage of these approaches is that their success is not contingent on a priori 
knowledge; therefore, potentially important differences, missed by focused approaches can be detected. Int. J. Mol. Sci. 2012, 13 1989 
 
 
The major disadvantages of these methods are that the functional impact of detected differences is 
often unclear and that the clonal differences might be evolutionarily neutral. In addition, many 
genome-wide approaches suffer from limited resolution. 
Karyotypic analysis based on chromosomal banding was frequently used in early reports on clonal 
heterogeneity [299,300]. In this technique, tumor cells are subjected to short-term culture followed by 
fixation and staining, which reveals a pattern of chromosomal banding in metaphase chromosomes. 
This method allows for the detection of large chromosomal abnormalities, but it has several pitfalls. 
Karyotypic analysis requires culturing the cells, which may lead to preferential outgrowth of selected 
tumor cell subpopulations, changing the representation of the original tumor. It is also labor-intensive 
and has low resolution. 
More recent publications usually rely on comparative genomic hybridization (CGH) to detect 
chromosomal aberrations. DNA from tumor and normal cells is differentially labeled with fluorescent 
probes and, in the classical form of the assay, hybridized to normal metaphase chromosomes. 
Fluorescent signal is then analyzed using specialized software, revealing regions of chromosomal 
losses and gains. CGH is one of the most widely used techniques in studies of intra-tumor clonal 
heterogeneity. It provides unbiased coverage of the whole genome. However, hybridization to 
metaphase chromosomes gives limited resolution, as small regions of deletion and amplification can be 
missed. Instead of metaphase chromosomes, differentially labeled DNA can be hybridized to genomic 
arrays, allowing for the detection of smaller-scale allelic imbalances up to the single-nucleotide level 
using single nuclear polymorphism (SNP) arrays [288]. Notably, analysis of chromosomal imbalances 
can be performed on the level of specific chromosomes (using chromosomal arrays) rather than on a 
whole-genome scale. Finally, clonal heterogeneity can potentially be detected by the analysis of DNA 
content, where tumor cells are stained with DNA-labeling dye and subjected to flow cytometric 
analysis (FACS). This approach reveals ploidy status and the distribution of cells in different phases of 
the cell cycle, and, in cases of large differences, allows for the detection of populations with distinct 
aneuploidy based on their shift from normal ploidy peaks [13,301-303]. The advantages of this method 
are that sampling issues are not much of a problem (discussed below) and that it is capable of resolving 
even highly intermixed subpopulations. However, its resolution is limited to the detection of clones 
that differ substantially in DNA content. Therefore, the method provides limited molecular insights 
unless distinct subpopulations are sorted and subsequently analyzed with more sensitive methods. 
5.1.4. Issues of Quantity and Quality 
Many methods of tumor heterogeneity analysis rely on microdissection of small, anatomically 
distinct sections of tumors from frozen or archived tissues. Microdissection allows for focusing the 
analysis on small, morphologically homogeneous populations and avoids contamination with   
non-malignant cells. However, the technique leads to increased DNA damage and thus reduced quality. 
The issue of DNA quality is especially pronounced in the analysis of archived formalin-fixed paraffin 
embedded tissues. Clonality remains as one of the most important hallmarks of neoplasms, but its 
analysis require careful test designs. The core of comprehensive clonality assays would include a 
complementary approach comprising the evaluation of structural abnormalities of key oncogenes and 
tumor suppressor genes (mutations, allelic imbalance) that control essential acquired capabilities in Int. J. Mol. Sci. 2012, 13 1990 
 
 
neoplasms. Pathway independent tests based on X-chromosome inactivation and the evaluation of 
epigenetic alterations such as methylation levels have a more restrictive application in female and 
specific tumor types with high imprinting levels, respectively. This approach would resolve the patch 
size problem that is frequently associated with clonal expansions, which can be highlighted in single 
marker analyses. 
Due to the low amount of starting material, many tumor heterogeneity analysis methods, especially 
those involving whole-genome analysis, rely on prior amplification of whole genomes. Several 
efficient methods for whole-genome amplification, relying either on PCR-based or isothermal DNA 
amplification, have been developed over the last decades. However, whole-genome amplification 
produces only a representation, not a replica, of the genome, so, inevitably, representation bias is 
introduced. This bias might be more pronounced in PCR-based techniques due to different efficiencies 
of amplification of fragments of different sizes and nucleotide composition. However, even isothermal, 
linear amplification techniques have been shown to suffer from substantial representation bias [304]. 
The issue of representation bias is most pronounced when the starting material is small (<10 cells) [18,28], 
culminating at the single-cell level. To some extent, bias issues can be reduced by using identically 
manipulated control samples. However, acquiring robust data often requires confirmation by 
independent methods, such as FISH analyses. 
5.2. Therapeutic Response 
It is possible that measurements of clonal heterogeneity can be useful irrespective of their utility in 
routine diagnostics. Substantial clonal heterogeneity between primary and metastatic tumors can pose a 
barrier to targeted therapy. Since biopsies of metastases are frequently unavailable, it would be worth 
investigating if the clonal heterogeneity of primary tumors is indicative of clonal divergence in 
metastatic outgrowths. The index of clonal diversity is a strong predictor for malignant progression in 
Barrett’s esophagus [13]; thus, it can be used for guiding treatment decisions. Although experimental 
evidence is still lacking, it is likely that Barrett’s esophagus is not a biological oddity and that clonality 
measurements will turn out to be of predictive value for malignant progression in other cancers as well. 
However, sampling multiple regions from the same tumor is impractical for most cancer types, and it 
is not yet clear if obtaining accurate clonality measurements can be achieved using current routine 
diagnostic methods. Also, though multiple biopsies from a single tumor might be impractical, the 
degree of cellular and molecular heterogeneity within a relatively small sample might also turn out to 
be of predictive value. 
Biological interactions between tumor clones could have a dramatic impact on tumor evolution, 
both in natural progression and in evolution in response to selection forces created by therapeutic 
interventions. This suggestion is supported by experimental studies in mice that have demonstrated 
that the growth of tumors resulting from transplanting mixtures of clones cannot be predicted from the 
behavior of tumors developed from individual clones [305]. Similarly, experimental tumors composed 
of multiple clones display different sensitivity to cytotoxic drugs compared to monoclonal tumors, as 
clonal interactions can either potentiate or inhibit therapeutic efficacy. Therefore, clonal heterogeneity 
adds an additional level of complexity to our understanding of the biology of tumor development and 
poses challenges for the development of successful therapies. As the field of cancer treatment is Int. J. Mol. Sci. 2012, 13 1991 
 
 
moving toward the development of targeted therapeutic approaches, the question of whether the 
expression of a therapeutic target in a biopsy is representative of the whole corresponding tumor 
becomes of primary importance [306]. For example, clonal heterogeneity involving different 
mutational statuses was documented for KRAS [301], tyrosine kinase growth factor receptors such as 
EGFR [307,308], and TP53 [13,309] genes, for which targeted therapy is currently being developed. 
Heterogeneous expression of the therapeutic target does not necessarily mean that the tumor will not 
be responsive to the treatment, especially if the targets are responsible for the “common good”. For 
example, targeting an angiogenic clone can also eliminate non-angiogenic “free rider” clones, which 
are dependent on the secretion of angiogenic factors. Still, clonal heterogeneity needs to be accounted 
for in the development of targeted therapy approaches, considering that high genetic heterogeneity of 
tumors means high probability of pre-existent clones that are resistant to therapeutic intervention and 
can be selected for by therapy, resulting in therapy failure. 
On the other hand, clonal heterogeneity can potentially be exploited for therapeutic benefit.   
Maley et al. proposed two such strategies of anti-cancer therapy. First, boosting the selective advantage 
of benign clones can be used to drive malignant clones to extinction. Second, the selective advantage 
of clones sensitive to a particular therapy can be boosted, allowing them to achieve clonal dominance, 
and then treatment can be applied. In silico modeling confirmed that these strategies can be much more 
efficient compared to standard cytotoxic therapies [310]. Unfortunately, these strategies are not yet 
feasible, as we lack the knowledge of how to single out or boost benign or chemosensitive clones. 
Gatenby and co-authors have recently proposed another strategy, termed adaptive therapy, which both 
accounts for the heterogeneity of tumor cells and takes advantage of it [219]. The conventional 
approach of adjuvant therapy is to hit tumors with the highest tolerated dose of cytotoxic drugs in a 
hope to kill the largest possible numbers of tumor cells, thereby decreasing the probability of the 
emergence of resistant mutants. However, this strategy would be expected to fail if resistant clones 
already exist before the treatment starts. Indeed, despite initial therapeutic responsiveness, treatment 
almost inevitably ends with the outgrowth of resistant tumors. Instead of completely eradicating 
tumors (which is not practically achievable in most cases), adaptive therapy aims to keep tumor size at 
bay by adjusting drug dose and timing of drug administration based on tumor response. This strategy 
prevents resistant variants from reaching fixation by maintaining the dominance of therapy-sensitive 
variants. Importantly, the feasibility of adaptive therapy is not contingent on knowledge of the exact 
mechanisms of the resistance, though the applicability of this idea has yet to be confirmed. 
Elimination of MDSC is a priority for cancer patients who are candidates for active immunotherapy. 
Likewise, limiting the accumulation and retention of MDSC during chronic inflammation may reduce 
the risk of developing cancers. The proinflammatory mediators that induce MDSC are particularly 
attractive targets for limiting this suppressor cell population, although there are several unknowns that 
make it difficult to decide which mediators to target. For example, it is not known whether the various 
proinflammatory factors induce MDSC through independent or overlapping pathways. If the pathways 
are independent, then it will be necessary to block individual pathways. In contrast, if the pathways 
merge, then a single drug aimed at a common molecule may be effective. Future studies may identify 
additional proinflammatory mediators or factors that independently or coordinately regulate the 
accumulation of MDSC. Regardless of the complexity of MDSC induction, reduction of this inhibitory Int. J. Mol. Sci. 2012, 13 1992 
 
 
population is essential, and a comprehensive understanding of the proinflammatory mediators that 
regulate MDSC will provide valuable information for future drug design.  
6. Conclusions and Future Directions 
The question of whether tumors are genetically homogeneous or rather consist of a number of 
genetically distinct clones is not of mere intellectual curiosity. Co-existence of distinct clones within a 
tumor can have profound clinical implications for disease progression, diagnosis, and therapeutic 
responses. Recently the intratumoral heterogeneity has been the subject of attention regarding response 
to therapy, concluding that a better result would be obtained by targeting several pathways [307,311]. 
This practical aspect is essential for a more effective personalized therapy, but there are biological 
aspects that would be worth considering. The neoplastic transformation evolves over a period of time, 
involving the phenotypic progression of tumor cells along with the interaction of the initiated cell with 
its microenvironment. The elucidation of the steps of cancer progression relates to the acquisition of 
invasive capability in intraepithelial lesions and metastatic potential in invasive malignancies and is of 
utmost importance in the differential diagnosis of neoplasms and in the establishment of more 
efficacious therapeutic regimens. This functional characterization of the particular stage of tumor will 
certainly allow for better diagnosis, staging, prognostication and treatment of cancers.  
Large amounts of evidence support the close clonal relationship of primary tumors and metastatic 
outgrowths. However, there is also strong evidence that suggests that metastatic spread can be an early 
event during tumor progression; thus, primary and metastatic tumors might become quite distinct 
genetically as they evolve. Some of the observed discrepancies might stem from technical issues, but it 
is plausible that the development of spontaneous human tumors is not confined to a single scenario. It 
is also possible that while many tumor cells are capable of early dissemination, only tumor cells that 
have acquired large numbers of oncogenic mutations are capable of initiating secondary tumors at 
metastatic sites. 
6.1. Future Directions 
Despite the substantial clinical significance of the issue of clonal heterogeneity, the subject remains 
very poorly explored. Therefore, a more systemic approach is needed to characterize the extent of 
clonal heterogeneity of different types and subtypes of cancers through different stages of tumor 
development, including disseminated tumor cells and metastases. Whether clonal heterogeneity 
changes in response to chemotherapy needs to be determined as well. Comprehensive characterization 
of tumor clonality is contingent on the development of approaches that can combine a focus on 
“driver” lesions with large-scale analysis. Advances in our understanding of the genetic composition of 
cancers make these analyses potentially feasible; however, methodology allowing for robust and   
cost-efficient analyses of small tumor samples is still lacking. 
Accounting for the biological interactions among distinct clonal populations within tumors might 
pose the biggest challenge. The co-existence of multiple clones within a tumor leads to a complex 
network of interactions both among the clones and between the clones and the tumor microenvironment. 
Thus, tumors are likely to behave as complex systems and should be treated as such, especially given 
that more simplistic views of tumors as homogeneous entities appear to provide satisfactory results Int. J. Mol. Sci. 2012, 13 1993 
 
 
only in model systems where the complexity of experimental tumors is low. While deciphering the full 
extent of the interactions occurring within tumors may be an impossible task, we might be able to 
identify critical links and use this knowledge to control or eliminate tumors. The knowledge from the 
fields of evolutionary biology and ecology provides key insights for improving the clinical 
management of cancer patients. 
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